Page last updated: 2024-11-05

aminophylline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Aminophylline is a bronchodilator medication used to treat asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. It is a combination of theophylline, a methylxanthine alkaloid, and ethylenediamine. Aminophylline works by relaxing the muscles in the airways, making it easier to breathe. It is typically administered intravenously or orally. Aminophylline is synthesized by reacting theophylline with ethylenediamine. Aminophylline has been studied extensively for its effects on the respiratory system, particularly its ability to relax airway smooth muscle. The medication has been shown to improve lung function and reduce symptoms of asthma and COPD. However, aminophylline can also cause side effects such as nausea, vomiting, headache, and insomnia. Due to its potential for side effects, aminophylline is typically reserved for patients who have not responded well to other bronchodilator medications. Aminophylline is important because it can be an effective treatment for respiratory conditions, but it is important to use it with caution and under the supervision of a healthcare professional.'

Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9433
CHEMBL ID1370561
CHEBI ID2659
SCHEMBL ID5037
MeSH IDM0000959

Synonyms (198)

Synonym
eufilina
ethylenediamine, theophylline
euufillin
rectalad aminophylline
cariomin
grifomin
theophyllin ethylenediamine
rectalad-aminophylline
etilen-xantisan tabl.
nsc-7919
lixaminol
aminocardol
eurphyllin
euphyllin
genophyllin
metaphyllin
cardophylin
theophylline ethylenediamine
metaphylline
theolone
dura-tab s.m. aminophylline
lasodex
theodrox
cardiofilina
tefamin
theolamine
linampheta
nsc7919
methophylline
aminodur
diuxanthine
diaphylline
thephyldine
somophyllin o
theophyllaminum
dobo
phyllocontin
stenovasan
variaphylline
317-34-0
aminophylline
norofilina
theophyllamine
aminophyllin
theophylline compound with ethylenediamine
by 108
theophyldine
ammophyllin
cardophyllin
vasofilina
theophyllin aethylendiamin
peterphyllin
diophllin
inophylline
phylcardin
cardiomin
phyllindon
neophyiline
theophyline ethylenediamine
miofilin
minaphil
syntophyllin
carena
somophyllin
theophylline-ethylenediamine
EU-0100014
aminophylline, >=98%, powder
PRESTWICK_93
NCGC00016113-02
lopac-a-1755
cas-317-34-0
NCGC00016113-01
ethophylline
DB01223
theophylline ethylenediamine (tn)
somophyllin (tn)
aminophylline (usp/inn)
D00227
aminophylline in sodium chloride 0.45% in plastic container
th/100
eufilina [polish]
aminofillina [dcit]
aminophylline dye free
theophylline, compd with ethylenediamine (2:1)
euufilin
truphylline
mudrane gg tablets
diophyllin
theophylline compound with ethylenediamine (2:1)
aminophylline in sodium chloride 0.45%
einecs 206-264-5
diaphilline
euphyllinum
nsc 7919
aminofilina [inn-spanish]
theophyllaminium
aminofilina [spanish]
mudrane gg-2 tablets
theophyllin aethylendiamin [german]
hsdb 221
theomin
dura-tab sm aminophylline
theophyllinum et ethylendiaminum
1h-purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd with 1,2-ethanediamine (2:1)
aminophyllinum [inn-latin]
aminodur dura-tabs
NCGC00093539-01
aminophylline ethylenediamine
NCGC00016113-03
AC-11138
A 1755 ,
1,3-dimethyl-7h-purine-2,6-dione; ethane-1,2-diamine
HMS1570D21
HMS2097D21
HMS3260C09
BCP9000293
aminophylline [usp:inn:ban:jan]
aminofillina
aminophyllinum
27y3kjk423 ,
unii-27y3kjk423
aminofilina
AKOS015951253
AKOS015960458
somopphyllin
aminophylline anhydrous
pulmophylline (new)
95646-60-9
pulmophyllin (new)
aminophylline(phyllocontin, truphylline)
BCP0726000247
FT-0622295
LP00014
S1673
CHEMBL1370561
theophylline-ethylenediamine anhydrous [ep impurity]
aminophylline [who-ip]
aminophylline [who-dd]
aminophylline [inn]
aminophyllinum [who-ip latin]
aminophylline [usp monograph]
theophylline and ethylenediamine
aminophylline [inci]
theophylline-ethylenediamine [ep monograph]
theophylline-ethylenediamine anhydrous
aminophylline [vandf]
aminophylline [mart.]
aminophylline [hsdb]
aminophylline [orange book]
aminophylline [mi]
CCG-221318
CCG-220820
CS-1936
HY-B0140
SCHEMBL5037
KS-5340
NCGC00260699-01
tox21_500014
FQPFAHBPWDRTLU-UHFFFAOYSA-N
W-106881
1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dione compound with ethane-1,2-diamine (2:1)
A2805
aminophylline, anhydrous
mfcd00013221
SR-01000872628-1
sr-01000872628
1,3-dimethyl-3,9-dihydro-1h-purine-2,6-dione compound with ethane-1,2-diamine (2:1)
HMS3655A19
theophylline-ethylenediamine; aminophylline
CHEBI:2659 ,
3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione, compd with 1,2-ethanediamine (2:1)
1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dione - ethane-1,2-diamine (2:1)
etilen-xantisan
aminophylline (truphylline)
HMS3714D21
SW199286-2
Q471763
1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dione hemiethane-1,2-diamine salt
1,3-dimethyl-1h-purine-2,6(3h,7h)-dione compound with ethane-1,2-diamine (2:1)
BCP23387
HMS3884G06
I10006
A875823
DTXSID40883359 ,
1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dionehemiethane-1,2-diaminesalt
BA166016
EN300-18532624
bis(1,3-dimethyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione); ethane-1,2-diamine
aminophyllinum (inn-latin)
aminofilina (inn-spanish)
theophylline-ethylenediamine anhydrous (ep impurity)
dtxcid101022896
1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dione-ethane-1,2-diamine (2:1)
aminophylline (mart.)
1h-purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compound with 1,2-ethanediamine(2:1)
aminophylline (usp:inn:ban:jan)
theophylline-ethylenediamine (ep monograph)
aminophylline (usp monograph)

Research Excerpts

Overview

Aminophylline (Am) is a phosphodiesterase inhibitor and is currently used as a bronchodilator. It is a competitive adenosine antagonist.

ExcerptReferenceRelevance
"IV aminophylline is an effective and safe early-stage treatment for patients with PDPH."( Aminophylline for treatment of postdural puncture headache: A randomized clinical trial.
Cui, Y; Guan, D; Ji, X; Li, C; Lian, Y; Liu, H; Ma, Z; Ren, M; Wan, C; Wang, C; Wu, C; Xie, J; Xie, N; Xue, F; Yan, F; Zhao, W; Zhong, P, 2018
)
2.54
"Aminophylline (Am) is a phosphodiesterase inhibitor and is currently used as a bronchodilator."( Interaction of aminophylline with photoilluminated riboflavin leads to ROS mediated macromolecular damage and cell death in benzopyrene induced mice lung carcinoma.
Arif, SH; Khan, S; Naseem, I, 2019
)
1.59
"Aminophylline is a nonselective phosphodiesterase inhibitor used to treat common lung diseases."( Aminophylline promotes mitochondrial biogenesis in human pulmonary bronchial epithelial cells.
Kong, S; Sun, R; Wei, G; Xu, T; Zhang, S, 2019
)
2.68
"Aminophylline is a competitive adenosine antagonist."( Aminophylline for bradyasystolic cardiac arrest in adults.
Green, R; Hurley, KF; Magee, K, 2013
)
2.55
"Aminophylline is a competitive adenosine antagonist."( Aminophylline for bradyasystolic cardiac arrest in adults.
Green, R; Hurley, KF; Magee, K, 2015
)
2.58
"Aminophylline is a complex of theophylline-ethylenediamine, where theophylline is the main component. "( Aminophylline (a theophylline-ethylenediamine complex) blocks ethanol behavioral effects in mice.
Arruda, Mde O; Assreuy, AM; de Carvalho, KM; de Souza Escudeiro, S; Lima, NM; Patrocínio, MC; Siqueira, RC; Soares, PM; Sousa, FC; Vasconcelos, SM; Viana, GS, 2009
)
3.24
"Aminophylline is a nonspecific adenosine receptor antagonist capable of reversing ischemia-induced bradyasystole in a variety of settings."( A randomized controlled trial of intravenous aminophylline for atropine-resistant out-of-hospital asystolic cardiac arrest.
Durkin, L; Mader, TJ; Scriver, G; Smithline, HA, 2003
)
1.3
"Aminophylline is a central respiratory stimulant and will decrease the incidence of PGE1-associated apnea and the need for intubation for apnea in infants with ductal-dependent congenital heart disease."( Aminophylline for the prevention of apnea during prostaglandin E1 infusion.
Charpie, JR; Crowley, DC; Kim, DW; Kulik, TJ; Lim, DS; Maher, KO, 2003
)
3.2
"Aminophylline is an adenosine receptor antagonist. "( Aminophylline as an adjunct diuretic for neonates--a case series.
Baker, EH; Farrer, KF; Ng, GY, 2005
)
3.21
"Aminophylline is an antiasthmatic drug and a known phosphodiesterase inhibitor."( Photodynamic inactivation of trypsin by the aminophylline-riboflavin system: involvement of hydroxyl radical.
Ali, I; Hasan, N; Naseem, I, 2006
)
1.32
"Aminophylline proved to be an effective adenosine antagonist when ejected as an anion, especially from alkaline solution."( Aminophylline and theophylline derivatives as antagonists of neuronal depression by adenosine: a microiontophoretic study.
Perkins, MN; Stone, TW, 1980
)
2.43
"Aminophylline is an effective prophylaxis for postextubation apnea in the preterm infant but does not affect maximal inspiratory force or increase the success rate of extubation in this patient population."( A randomized, controlled trial of aminophylline in ventilatory weaning of premature infants.
Barrington, KJ; Finer, NN, 1993
)
2.01
"Aminophylline is a respiratory stimulant commonly used for the treatment of central apnea. "( Aminophylline modulation of the mouse respiratory network changes during postnatal maturation.
Hanefeld, F; Ramirez, JM; Richter, DW; Wilken, B, 2000
)
3.19
"Aminophylline is an effective modality for acute treatment of hyperkalemia, though it is less effective than insulin-dextrose infusion. "( Comparison of aminophylline and insulin-dextrose infusions in acute therapy of hyperkalemia in end-stage renal disease patients.
Kishore, K; Mahajan, SK; Mangla, M, 2001
)
2.11
"Aminophylline is a potent antagonist at purinoceptor level."( Role of purinergic system in tracheobronchial reactivity of healthy and bronchopathic subjects.
Carapella, N; Filippelli, A; Loffreda, A; Marmo, E; Matera, MG; Montanaro, C; Santagata, A; Servodio, R; Susanna, V, 1990
)
1
"Aminophylline (A) is a proconvulsant in adult rats. "( Proconvulsant effects of aminophylline during amygdala kindling in developing rats.
Pasternak, JF; Suyeoka, GM; Trommer, BL, 1989
)
2.02

Effects

Aminophylline has been widely used in the treatment of apneic episodes in premature infants. It has been shown to produce a reduction in cerebral blood flow (CBF) in animal models and patients with neurologic symptoms or signs.

ExcerptReferenceRelevance
"Oral aminophylline has a favourable effect on exercise induced chest pain threshold in patients with syndrome X. "( Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X).
Calvino, R; Elliott, PM; Hann, C; Kaski, JC; Krzyzowska-Dickinson, K, 1997
)
1.16
"Aminophylline has been shown to have anti-inflammatory effects; however, the role of aminophylline in sepsis, a disease characterized by immune dysregulation, is unknown."( Alterations in the gut microbiome and metabolome profiles of septic rats treated with aminophylline.
Ding, X; Duan, Y; Guo, Y; Li, Y; Sun, G; Xie, L; Zhao, H, 2022
)
1.67
"Aminophylline injection has been on an intermittent nation-wide shortage due to manufacturing delays leaving a need for an alternative reversal agent for regadenoson-associated side effects. "( Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal.
Page, RL; Pham, VA; Quaife, RA; Raines, J; Shakowski, C, 2023
)
2.35
"Aminophylline has anti-asthma and anti-inflammatory effects."( Adjunctive sepsis therapy with aminophylline (STAP): a randomized controlled trial.
Dai, D; Ding, X; Duan, X; Fang, Y; Han, B; Liu, H; Liu, S; Luo, Y; Shi, X; Sun, T; Wang, D; Wang, H; Wang, Y; Xu, W; Yang, J; Zhang, R; Zhang, S; Zhang, X, 2022
)
1.73
"Aminophylline has such clinical effects as improving pulmonary ventilation, decrease in apnoea frequency, and improving blood gas indices."( Immunological outcomes in infants with ROP after dexamethasone and aminophylline.
Balashova, L; Bykovskaya, S; Kantardgy, E; Korobova, L; Kuznetsova, Y; Mukhin, V; Popov, A, 2020
)
1.52
"Aminophylline has been shown to reduce severe renal dysfunction in neonates after perinatal asphyxia."( Aminophylline for renal protection in neonatal hypoxic-ischemic encephalopathy in the era of therapeutic hypothermia.
Cho, SH; Chock, VY; Frymoyer, A, 2021
)
2.79
"Aminophylline has been demonstrated to be effective in improving renal functions of the infants suffering from acute kidney injury (AKI) due to perinatal asphyxia. "( A single dose of aminophylline administration during therapeutic hypothermia; does it make a difference in glomerular filtration rate?
Aydemir, O; Gunes, D; Surmeli Onay, O; Tekin, N, 2021
)
2.4
"Aminophylline has been widely used in the treatment of apneic episodes in premature infants. "( Neurodevelopmental Outcomes in Very Low Birth Weight Infants Using Aminophylline for the Treatment of Apnea.
Chen, HL; Lee, PL; Lee, WT; Lu, CC; Tey, SL, 2016
)
2.11
"Aminophylline has been reported to be effective in the prevention of PDPH in some clinical studies, but its efficacy for the treatment of PDPH has been unproven."( A Multicenter Clinical Study on Treating Post-Dural Puncture Headache with an Intravenous Injection of Aminophylline.
Chen, Y; Guan, D; Lian, Y; Miao, Y; Wang, L; Wu, C; Xie, N; Zheng, Y, 2016
)
1.37
"Aminophylline has been used extensively to treat exacerbations in acute asthma settings; however, it's role is unclear especially with respect to any additional benefit when added to inhaled beta(2)-agonists."( Addition of intravenous aminophylline to inhaled beta(2)-agonists in adults with acute asthma.
Milan, SJ; Nair, P; Rowe, BH, 2012
)
1.41
"Aminophylline has significant anti-hypoxia and anti-oxidation effects at high altitude."( Anti-hypoxia and anti-oxidation effects of aminophylline on human with acute high-altitude exposure.
Chen, B; Chen, L; Qin, RB; Wang, GY; Xi, SL; Yang, B, 2007
)
2.05
"Oral aminophylline has a favourable effect on exercise induced chest pain threshold in patients with syndrome X. "( Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X).
Calvino, R; Elliott, PM; Hann, C; Kaski, JC; Krzyzowska-Dickinson, K, 1997
)
1.16
"Aminophylline has not been studied as an adjunct diuretic in critically ill children. "( Aminophylline in the treatment of fluid overload.
Pollack, MM; Pretzlaff, RK; Vardis, RJ, 1999
)
3.19
"Aminophylline has not been found by most studies to improve outcomes and the narrow therapeutic range and unfavorable safety profile relegate it to a last-line agent or no use at all."( Treatment of acute asthma. A new look at the old and at the new.
Silverman, R, 2000
)
1.03
"Aminophylline has been used extensively in acute asthma, but its role is unclear especially with respect to any additional benefit when added to beta2-agonists."( Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma.
Belda, J; Parameswaran, K; Rowe, BH, 2000
)
2.06
"Aminophylline (1 mM) has effects qualitatively similar to cAMP and DBcAMP, while imidazole has opposite effects."( Effects of adenosine 3',5'-monophosphate, dibutyryl adenosine 3',5'-monophosphate, aminophylline, and imidazole on renal cellular calcium metabolism.
Borle, AB; Uchikawa, T, 1979
)
1.21
"Aminophylline has been reported to augment diaphragmatic contraction, although this remains a controversial finding. "( Effects of aminophylline on regional diaphragmatic shortening after thoracotomy in the awake lamb.
Fratacci, MD; Kacmarek, RM; Kimball, WR; Polaner, DM; Torres, A; Wain, JC; Zapol, WM, 1992
)
2.12
"Aminophylline has been shown to dramatically reduce the filtering capacity of the lung in dogs during venous air embolism. "( Effect of aminophylline on transpulmonary passage of venous air emboli in pigs.
Brubakk, AO; Jenssen, BM; Vik, A, 1991
)
2.13
"Aminophylline therapy has undergone change in the past decade. "( Aminophylline toxicity.
Albert, S, 1987
)
3.16
"Aminophylline in a low dose has been shown to reverse diazepam sedation. "( Adenosine in the inhibition of diazepam sedation by aminophylline.
Arvidsson, S; Ekström-Jodal, B; Martinell, S; Niemand, D; Svedmyr, N, 1986
)
1.96
"Aminophylline has been shown to produce a reduction in cerebral blood flow (CBF) in animal models and patients with neurologic symptoms or signs. "( The effect of aminophylline on cerebral blood flow in patients with chronic obstructive pulmonary disease.
Alford, PT; Bowton, DL; McLees, BD; Prough, DS; Stump, DA, 1987
)
2.08

Actions

Aminophylline did not cause tachycardia and this difference compared with the beta-agonists on pulse rate was statistically significant (p less than 0.001) The drug markedly increased the ED(50) value of topiramate during the chronic treatment in mice.

ExcerptReferenceRelevance
"Aminophylline at a lower dose of 25 mg/kg did not affect significantly the ED(50) value of topiramate in the acute experiment, but the drug markedly increased the ED(50) value of topiramate during the chronic treatment in mice."( Pharmacokinetic and pharmacodynamic interactions of aminophylline and topiramate in the mouse maximal electroshock-induced seizure model.
Czuczwar, SJ; Jankiewicz, K; Jankiewicz, M; Luszczki, JJ, 2007
)
1.31
"Aminophylline did not cause tachycardia and this difference compared with the beta-agonists on pulse rate was statistically significant (p less than 0.001)."( Comparative study of the effects of intravenous administration of aminophylline, salbutamol and terbutaline in patients suffering from reversible airways obstruction.
Bell, R; Chatterjee, SS; Jayaswal, R; Sahay, JN, 1984
)
1.23
"aminophylline did not produce adequate serum theophylline concentrations or eliminate the need for a second bolus dose in most pediatric patients with acute exacerbations of asthma."( Adequacy of recommended aminophylline loading doses in children.
Godley, PJ; Maxwell-Rubin, M; Paap, CM, 1994
)
1.32
"Aminophylline was shown to inhibit Amaranthus cyclic AMP phosphodiesterase activity."( Evidence against an involvement of cyclic nucleotides in the induction of betacyanin synthesis by cytokinins.
Elliott, DC; Murray, AW, 1975
)
0.98
"Aminophylline is thought to increase respiratory drive centrally."( The effect of aminophylline on the excursions of the diaphragm in preterm neonates. A randomized double-blind controlled study.
Fong, K; Heyman, E; Heyman, Z; Ohlsson, A, 1991
)
1.36
"The aminophylline-evoked increase in short-circuit current resulted from a reduction in net sodium absorption and abolishment of chloride absorption without a significant effect on residual flux."( Epithelial transport in guinea-pig proximal colon: influence of enteric neurones.
Kuwahara, A; Radowicz-Cooke, HJ, 1988
)
0.76
"Aminophylline was found to produce changes in the reduced APD similar to those caused by the sympathomimetic amines."( Influence of glucose on the transmembrane action potential of papillary muscle. Effects of concentration, phlorizin and insulin, nonmetabolizable sugars, and stimulators of glycolysis.
MacLeod, DP; Prasad, K, 1969
)
0.97

Treatment

Pretreatment with aminophylline, an adenosine receptor antagonist, either abolished (blood pressure, minute ventilation, and end-tidal CO2) or markedly attenuated (MSNA and heart rate) the effects of dipyridamole during room air breathing. Pretreatment increased the number of cardioversion applications required to terminate ventricular fibrillation.

ExcerptReferenceRelevance
"Aminophylline treatment induces the expression of transcriptional coactivator PGC-1α and transcriptional factors NRF1 and TFAM."( Aminophylline promotes mitochondrial biogenesis in human pulmonary bronchial epithelial cells.
Kong, S; Sun, R; Wei, G; Xu, T; Zhang, S, 2019
)
2.68
"Aminophylline treatment significantly reduced serum creatinine, compared with group C."( Aminophylline Effect on Renal Ischemia-Reperfusion Injury in Mice.
Choi, JW; Han, D; Jung, HS; Kim, DW; Noh, SJ; Seo, K, 2017
)
2.62
"Aminophylline treatment improved the renal function and indexes of renal inflammation, which suggests that it provided reno-protection against renal I/R injury."( Aminophylline Effect on Renal Ischemia-Reperfusion Injury in Mice.
Choi, JW; Han, D; Jung, HS; Kim, DW; Noh, SJ; Seo, K, 2017
)
3.34
"Aminophylline treatment immediately after hypoxic insult significantly improved long-term neurobehavioral achievements."( Protective effects of methylxanthines on hypoxia-induced apoptotic neurodegeneration and long-term cognitive functions in the developing rat brain.
Akhisaroglu, M; Aksu, I; Aykan, S; Cilaker, S; Duman, N; Genc, S; Kumral, A; Ozkan, H; Sutcuoglu, S; Tugyan, K; Yesilirmak, DC; Yilmaz, O, 2010
)
1.08
"Aminophylline-treated patients reported more palpitations/arrhythmias (OR 3.02; 95% CI 1.15 to 7.90; 6 studies; n = 249) and vomiting (OR 4.21; 95% CI 2.20 to 8.07; 7 studies; n = 321); however, no significant difference was found in tremor (OR 2.60; 95% CI 0.62 to 11.02; 5 studies; n = 249)."( Addition of intravenous aminophylline to inhaled beta(2)-agonists in adults with acute asthma.
Milan, SJ; Nair, P; Rowe, BH, 2012
)
1.41
"Aminophylline treatment failed to prevent these endotoxemia-induced respiratory and hemodynamic manifestations of sepsis, but significantly improved the acid-base imbalance that developed during surgical procedures in saline-treated control rats."( Aminophylline therapy during endotoxemia in anesthetized spontaneously breathing rats.
Camacho, MT; Fakioglu, H; Gelvez, J; Glover, ML; Olarte, JL; Torbati, D; Wolfsdorf, J, 2004
)
2.49
"Aminophylline pretreatment resulted in a 2.8-fold potentiation of the hypotensive effects of a continuous infusion of SNP."( Aminophylline potentiates sodium nitroprusside-induced hypotension in the dog.
Ashton, JP; Murad, F; Pearl, RG; Rosenthal, MH, 1984
)
2.43
"Aminophylline treatment of pregnant rabbits for 2 days, beginning at 25.5 days gestation, produced a significant increase in total phospholipid in fetal lung tissue at 27.5 days gestation, 8.92 +/- 0.76 (mean +/- SEM) mg/g wet lung weight, compared with 5.46 +/- 0.83 in saline-injected control animals (p less than 0.005). "( Effect of aminophylline and caffeine on total and surfactant phospholipid in fetal rabbit lung.
Corbet, A; Cregan, J; Frink, J; Landers, S; Rudolph, AJ, 1984
)
2.11
"Aminophylline treatment significantly suppressed t-2 but not t-1."( Double-peaked positive chronotropic responses of isolated and cross-perfused dog atria to ATP.
Chiba, S; Kobayashi, M; Shimotori, M, 1983
)
0.99
"Aminophylline-treated patients required fewer nebulizations of albuterol (10.3 +/- 3.8 compared with 16.4 +/- 5.3; mean difference, -6.1; CI, -10.3 to -1.8) and less total dosage (34 +/- 16 mg compared with 70 +/- 34 mg; mean difference, -36 mg; CI, -60.6 to -11.3 mg P = 0.02)."( Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma?
Aull, L; Harman, E; Hendeles, L; Huang, D; O'Brien, RG; Reents, S; Shieh, G; Visser, J, 1993
)
1.52
"Aminophylline treatment was associated with a statistically significant reduction in time-averaged mean velocity from baseline (P < 0.001) and an increase in heart rate (P < 0.001) at all timepoints. "( Aminophylline and Doppler time-averaged mean velocity in the middle cerebral artery in preterm neonates.
Fong, K; Govan, JJ; Myhr, T; Ohlsson, A; Ryan, ML, 1995
)
3.18
"The aminophylline treated group had higher values of PEFR at 12 (PEFR 8 L/min or 2.3%) and 24 hours (PEFR 22 L/min or 6.4%), but these were not significant (p>0.05)."( Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma.
Belda, J; Parameswaran, K; Rowe, BH, 2000
)
1.09
"In aminophylline pretreated rats the values were 84.14 +/- 2.03, 68.06 +/- 1.24, 54.28 +/- 1.96 and 39.58 +/- 2.31 mA at 25 mgkg-1 (0.06 mmolekg-1), 50 mgkg-1 (0.12 mmolekg-1), 100 mgkg-1 (0.24 mmolekg-1) and 150 mgkg-1 (0.36 mmolekg-1), i.p."( A comparative study of aminophylline and acepifylline on reversal phenomenon of anticonvulsant drug efficacy in electroshock model of seizures in rats.
Chakrabarti, A,
)
0.96
"The aminophylline-treated group was also similar to control with respect to baseline ejection fraction, amount of post-procedure hydration, age, blood pressure and the use of nephrotic drugs."( Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures.
Coyne, EP; Harris, M; Kapalis, MJ; McKinney, D; Shammas, NW, 2001
)
2.23
"Aminophylline treatment (100 mg/kg) markedly increased mortality following embolization."( Influence of various agents on the development of brain edema in the rat following microembolism. Protective effect of gamma-butyrolactone.
Beley, A; Beley, P; Bralet, AM; Bralet, J,
)
0.85
"The aminophylline-treated group retained significantly more gas at low pressures on the deflation curve (Table 2) and had significantly more phosphatidylcholine recovered in lung lavage fluid (Table 3) than the other groups."( Effects of cortisol and aminophylline upon survival, pulmonary mechanics, and secreted phosphatidyl choline of prematurely delivered rabbits.
Barrett, CT; Gilden, C; Kaplan, SA; Phelps, DL; Sevanian, A, 1978
)
1.05
"The aminophylline-treated patients showed a significantly more rapid reversal of sedation, but after 30 min there was no difference between the two groups."( Benzodiazepine antagonism by aminophylline.
Caldara, A; Fogh, B; Høegholm, A; Pedersen, C; Steptoe, P, 1989
)
1.05
"Aminophylline-treated mouse bone marrow-derived mast cells exhibit a hyperresponsiveness to adenosine addition (10(-6) to 10(-4) mol/L) at the time of secretagogue challenge coincident with an up regulation of adenosine receptor numbers. "( Aminophylline exposure alters mouse bone marrow-derived mast cell adenosine responsiveness.
Gruber, HE; Marquardt, DL; Wasserman, SI, 1986
)
3.16
"Aminophylline-treated rats had shorter thiopental sleep-times than saline-treated controls."( Aminophylline shortens thiopental sleep-time and enhances noradrenergic neurotransmission in rats.
Louie, GL; Maze, M; Nicholls, EA; Prokocimer, PG, 1986
)
2.44
"Aminophylline-treated cats killed after 3 hours of recirculation showed significantly reduced hyperemia and edema and no leakage of Evans blue, which was present in all untreated cats killed after 3 hours or 3 days of recirculation."( Effect of aminophylline on postischemic edema and brain damage in cats.
Klatzo, I; Seida, M; Vass, K; Wagner, HG, 1988
)
1.4
"Thus aminophylline pretreatment did alleviate the hypoxic ventilatory decline, although the associated alterations in breathing pattern were uncharacteristic."( Ventilatory response to sustained hypoxia after pretreatment with aminophylline.
Anthonisen, NR; Easton, PA, 1988
)
0.97
"Aminophylline-treated litters had greater body weights, an improved survival rate, and an increased amount of phosphatidylglycerol in lung lavage fluid."( Effect of aminophylline on lung maturation in preterm rabbit fetuses.
Barbati, A; Cosmi, EV; Del Bolgia, F; Di Renzo, GC; Grossmann, G; Lachmann, B; Robertson, B; Saitto, C, 1986
)
1.39
"Aminophylline pretreatment markedly enhanced the length and severity of elicited seizures from hippocampal (dentate gyrus) or perforant pathway stimulation."( Modification of excitation and inhibition evoked in dentate gyrus by perforant path stimulation: effects of aminophylline and kindling.
Albertson, TE; Joy, RM, 1986
)
1.21
"Aminophylline pretreatment reduced reactive hyperemia below the control level even in the presence of an intracoronary infusion of adenosine."( Intracoronary adenosine enhances myocardial reactive hyperemia after brief coronary occlusion.
Abe, Y; Hyodo, T; Nakatsu, T; Saito, D; Takeda, K; Tani, H; Ueeda, M; Yamada, N, 1985
)
0.99
"Treatment with aminophylline and isoproterenol improved the overall blood flow in the spinal cord."( Effect of aminophylline and isoproterenol on spinal cord blood flow after impact injury.
DeCrescito, V; Dow-Edwards, D; Flamm, ES; Tomasula, JJ, 1980
)
1
"Pretreatment with aminophylline [15 mg Kg-1, i.p.], a phosphodiesterase inhibitor, restored the fasting-depressed NE-stimulated NST to the fed level."( Effects of fasting and aminophylline on norepinephrine-stimulated non-shivering thermogenesis.
Christopherson, RJ; Jourdan, ML; Wang, LC, 1984
)
0.9
"Treatment with aminophylline, according to the nomogram published by Jusko and coworkers, was monitored in 13 patients suffering from acute exacerbations of COPD. "( Monitoring aminophylline therapy using Jusko's dosage guidelines.
Alférez, NP; Calandre, EP; Mata, GV; Morales, AM; Moreno, E; Perez de la Cruz, AJ, 1983
)
1.01
"Pretreatment with aminophylline, an adenosine receptor antagonist, either abolished (blood pressure, minute ventilation, and end-tidal CO2) or markedly attenuated (MSNA and heart rate) the effects of dipyridamole during room air breathing."( Role of arterial chemoreceptors in mediating the effects of endogenous adenosine on sympathetic nerve activity.
Engelstein, ED; Lerman, BB; Rea, RF; Somers, VK, 1994
)
0.61
"Pretreatment with aminophylline increased the number of cardioversion applications required to terminate ventricular fibrillation."( Aminophylline fails to improve the outcome of cardiopulmonary resuscitation from prolonged ventricular fibrillation: a placebo-controlled, randomized, blinded experimental study.
Ashline, PT; Hayes, WJ; Kempler, P; Littmann, L; Norton, HJ; Raymond, RM; Svenson, RH; Tatsis, GP; Tuntelder, JR, 1994
)
2.05
"Treatment with aminophylline (6 mg/kg bolus followed by 0.1-0.5 mg/kg/hour x 7 days) significantly prolonged the event-free survival of SCID mice (median survival of control mice, 39 days, N = 79; median survival of aminophylline-treated mice, 60 days, N = 10; P < 0.0001 by log-rank test) and it was more effective than treatment with vincristine (median survival = 51 days, N = 5) or L asparaginase (median survival = 44 days, N = 5)."( In vitro and in vivo anti-leukemic efficacy of cyclic AMP modulating agents against human leukemic B-cell precursors.
Chandan-Langlie, M; Chelstrom, LM; Myers, DE; Uckun, FM, 1996
)
0.63
"Pretreatment with aminophylline has been shown to protect against various types of acute lung injury. "( Postexposure treatment with aminophylline protects against phosgene-induced acute lung injury.
Gurtner, GH; Kennedy, TP; Sciuto, AM; Strickland, PT,
)
0.76
"treatment with aminophylline (AMPH) on the risk of calcium phosphate and struvite stone formation."( Intravenous aminophylline increases the degree of saturation of urine with calcium phosphate and struvite.
Głuszek, J; Maciejewski, J; Musialik, D; Siwińska, A, 1997
)
1.02
"Treatment with aminophylline is associated with an increased risk of vomiting."( Intravenous aminophylline for acute severe asthma in children over 2 years using inhaled bronchodilators.
Bassler, D; Ducharme, FM; Mitra, A, 2001
)
1.03
"Treatment with aminophylline or dibutyryl cyclic AMP for 24 hr, resulted in a 25% (P less than 0.025) and 75% (P less than 0.001) decrease, respectively, in the glycogen content of the explants."( Influence of aminophylline and cyclic AMP on glycogen metabolism in fetal rat lung in organ culture.
Gross, I; Maniscalco, WM; Wilson, CM, 1979
)
0.97
"Treatment with aminophylline and/or ephedrine also significantly reduced ethanol's effects on the electroencephalogram and motor coordination."( Reversal of ethanol intoxication in humans: an assessment of the efficacy of L-dopa, aminophylline, and ephedrine.
Alkana, RL; Birch, H; Cohen, HB; Noble, EP; Parker, ES, 1977
)
0.82
"Pretreatment with aminophylline potentiated the Hi effect, indicating that Hi lipolysis may be intimately related to cyclic AMP."( Histamine lipolysis I: changes in the free fatty acid levels of dog plasma after intravenous infusion of histamine.
Akiyama, Y; Kamei, C; Mukai, T; Tasaka, K, 1990
)
0.6
"Pretreatment with aminophylline prevented the increase in lung leak index for 125I-albumin (0.28 +/- 0.03 after phosgene vs."( Dibutyryl cAMP, aminophylline, and beta-adrenergic agonists protect against pulmonary edema caused by phosgene.
Bysani, GK; Gurtner, GH; Hasty, D; Hoidal, JR; Hopkins, C; Kennedy, TP; Lazar, R; Michael, JR; Sciuto, AM; Tolley, E, 1989
)
0.95
"Pretreatment with aminophylline significantly attenuated the hypoxic ventilatory decline."( Aminophylline effects on ventilatory response to hypoxia and hyperoxia in normal adults.
Anthonisen, NR; Berezanski, D; Georgopoulos, D; Holtby, SG, 1989
)
2.04
"Pretreatment with aminophylline (p less than 0.01) or isoproterenol (p less than 0.001) completely prevented the increase in pulmonary artery pressure after acid instillation."( Isoproterenol or aminophylline attenuate pulmonary edema after acid lung injury.
Farrukh, I; Gurtner, GH; Michael, JR; Mizus, I; Summer, W, 1985
)
0.93
"Treatment with aminophylline during normoxia was associated with an increase in tidal volume."( Aminophylline reduces hypoxic ventilatory depression without increasing catecholamines.
Althaus, JS; Bruce, RD; Darnall, RA,
)
1.91
"Pretreatment with aminophylline (a blocker of adenosine receptors), in doses of 40 mg/kg, 30 minutes prior to lidocaine, potentiated seizure development and the manifestations of irritable-aggressive behavior in experimental animals."( Facilitation and antagonism of lidocaine-kindled seizures: the behavioral feature.
Lekić, DM, 1988
)
0.6
"Pretreatment with aminophylline (20 mg/kg) reduced the fall in Taw by 31% and reduced the increase in Rcs by 53%."( Aminophylline reduces air-flow-induced constriction in the canine lung periphery.
Adkinson, NF; Freed, AN; Menkes, HA; Wang, D, 1988
)
2.04
"Pretreatment with aminophylline decreased the amount of ventilatory depression (p less than 0.05) by preventing a decrease in respiratory frequency."( Aminophylline reduces hypoxic ventilatory depression: possible role of adenosine.
Darnall, RA, 1985
)
2.04
"Treatment with aminophylline also stimulated the metabolism of 20-methylcholanthrene and 7,12-dimethylbenz (a) anthracene."( Genetic control of the regulation of cell susceptibility to carcinogenic polycyclic hydrocarbons by cyclic AMP.
Huberman, E; Sachs, L; Yamasaki, H, 1974
)
0.59

Toxicity

Theophylline may be a safe and effective alternative to reverse regadenoson-associated side effects. The FEV1 improved continually throughout the study to a similar extent in both treatment groups, but the patients treated with aminophyllines had significantly more adverse effects.

ExcerptReferenceRelevance
" In adult rats, the LD50 of caffeine and aminophylline was the same after 24 h and after 1 week of observation: caffeine 265 mg/kg, and aminophylline 202 mg/kg (theophylline base 172 mg/kg)."( Comparative toxicity of caffeine and aminophylline (theophylline ethylenediamine) in young and adult rats.
Gorodischer, R; Kaplanski, J; Warszawski, D, 1978
)
0.8
"The LD50 of aminophylline in adult mice differed from young mice and rats of both ages, in which the values were remarkably similar (Table 1)."( Toxicity and tissue distribution of aminophyline in neonatal and adult mice and rats.
Neese, AL; Soyka, LF, 1977
)
0.64
" Use of parenteral aminophylline to treat adverse events associated with intravenous dipyridamole brought complete relief of symptoms in 439 of 454 patients (96."( The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group.
Kempthorne-Rawson, J; Ranhosky, A, 1990
)
0.61
" Toxic levels of theophylline were associated with hypokalemia, hypophosphatemia, hyperglycemia, metabolic acidosis, and hypotension in both the patient and the experimental series."( Theophylline toxicity and the beta-adrenergic system.
Curtis, GP; Kearney, TE; Manoguerra, AS; Ziegler, MG, 1985
)
0.27
" Intravenous dipyridamole is safe for nonexercise stress testing and has few serious side effects."( Safety of intravenous dipyridamole for stress testing with thallium imaging.
Boucher, CA; Gilliland, Y; Guiney, TE; Homma, S; Strauss, HW, 1987
)
0.27
"In accordance with a case report of a 7-year-old boy with bronchial asthma, who was twice treated with aminophylline and each time reacted upon this with an aggressive behaviour, which was completely abolished after stopping the medication and which did not appear after application of theophylline, we became suspicious, that this side effect could be due only to the ethylenediamine."( [Aggressive behavior as a side effect of ethylenediamine (but not of theophylline)].
Niggemann, B, 1985
)
0.48
" In contrast to halothane induction of enflurane anesthesia following aminophylline appears to be safe and does not cause cardiac arrhythmias."( Safety of enflurane following administration of aminophylline in experimental animals.
Berger, JM; Ricker, SM; Roe, SD; Stirt, JA; Sullivan, SF, 1981
)
0.75
" The dose of aminophylline (125 mg/hour) previously recommended results in a toxic serum theophylline concentration in a majority of patients if the infusion is continued for more than 24 to 48 hours."( Theophylline toxicity after the use of aminophylline in the treatment of cerebral vasospasm.
Bailey, RT; Blouin, RA; Rapp, RP; Young, B, 1981
)
0.9
" Only 44% had theophylline serum concentrations (Cp) in the optimum range (10-20 mg/l), while in 36% of patients potentially toxic Cp values were observed."( [Relation of dose, serum concentration and side effects in intravenous aminophylline therapy].
Follath, F; Katz, G; Kewitz, G; Vozeh, S, 1981
)
0.5
" 4 of 6 patients with toxic signs and symptoms attributed to methotrexate and unrelieved by steroids, epidural blood patch, promethazine, 5-hydroytryptamine antagonists, paracetamol, and narcotics, had complete resolution of neurotoxicity after or during a 1-h infusion of aminophylline; 2 others had a pronounced improvement but persistent nausea."( Aminophylline for methotrexate-induced neurotoxicity.
Bernini, JC; Chappell, WB; Fort, DW; Griener, JC; Kamen, BA; Kane, BJ, 1995
)
1.91
" The outcome variables were: duration of hospitalization, percent of predicted peak expiratory flow rates recorded at 12-hour intervals, number of albuterol treatments required, and adverse effects."( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations.
Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994
)
1.73
" In the Am group, 6 of the 14 patients who entered the study experienced significant adverse effects consisting of nausea, emesis, headache, abdominal pain, and palpitations."( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations.
Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994
)
1.73
"There is no benefit and considerable risk of adverse effects associated with the use of Am in hospitalized asthmatic children."( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations.
Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994
)
1.73
"This study examined mainly the adverse effects of 201Tl myocardial scintigraphy with dipyridamole (D-Tl) in 73 elderly patients over 70 years old in comparison with those in 65 younger patients."( Safety and accuracy of dipyridamole thallium myocardial scintigraphy in elderly patients.
Ando, H; Ando, S; Ashihara, T; Fukuoka, T; Fukuyama, T; Higuchi, Y; Mitsuoka, W; Tagawa, H, 1993
)
0.29
" All of these animals also survived with no apparent adverse effects."( Reversal of propranolol blockade of adrenergic receptors and related toxicity with drugs that increase cyclic AMP.
Alleva, FR; Balazs, T; Joseph, X; Vick, JA; Whitehurst, VE; Zhang, J, 1999
)
0.3
" In Ex I and II, no subjects had adverse effects and in Ex I no influence on ECG was seen."( Usefulness and safety of theophylline injection form (Theodrip) for the treatment of acute asthma.
Fukui, H; Katoh, H; Kawai, H; Kojima, J; Ohnishi, A; Onodera, K; Taniguchi, T, 2000
)
0.31
" In another instance heart block and hypotension was noted in association with a diltiazem and atenolol adverse interaction."( Aminophylline reversal of antihypertensive agent toxicity.
Roberge, RJ; Rosetti, JM; Rossetti, ML, 2001
)
1.75
" Reports of adverse events associated with the use of these non-prescription supplements have raised concerns in the United States regulatory community."( The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent.
Greenway, FL, 2001
)
0.31
" Theophylline, a re-emerging drug for the treatment of obstructive airway disease, has a narrow therapeutic index which precludes its safe use."( Free radicals and theophylline neurotoxicity : an experimental study.
Gulati, K; Ray, A; Vijayan, VK, 2007
)
0.34
" Secondary end-points were the rate of control of chronic cough at each step of therapy, the duration of treatment required, changes in cough symptom score, health-related quality of life and possible adverse effects."( Efficacy and safety of modified sequential three-step empirical therapy for chronic cough.
Li, X; Liang, S; Liu, B; Lü, H; Qiu, Z; Wang, L; Wang, Y; Wei, W; Yu, L, 2010
)
0.36
"It is unknown whether the standardized intravenous aminophylline administration following regadenoson-stress can prevent the gastrointestinal and other adverse effects associated with regadenoson."( Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
Calvin, JE; Doukky, R; Jain, S; Kiriakos, R; Morales Demori, R; Mwansa, V, 2012
)
0.84
"In a randomized, double-blinded, placebo-controlled clinical trial we compared the frequency and severity of regadenoson adverse effects in those who received 75 mg of intravenous aminophylline versus a matching placebo administered 2 minutes after regadenoson or 90 seconds post-radioisotope injection."( Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
Calvin, JE; Doukky, R; Jain, S; Kiriakos, R; Morales Demori, R; Mwansa, V, 2012
)
0.78
" Additionally, aminophylline use was associated with 34% reduction in the secondary endpoint of any regadenoson adverse effects [55 (44."( Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
Calvin, JE; Doukky, R; Jain, S; Kiriakos, R; Morales Demori, R; Mwansa, V, 2012
)
0.94
"This trial supports the routine administration of IV-aminophylline to reduce the frequency and severity of adverse effects associated with regadenoson-stress."( Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
Calvin, JE; Doukky, R; Jain, S; Kiriakos, R; Morales Demori, R; Mwansa, V, 2012
)
0.84
"Intravenous administration of aminophylline is widely adopted to reverse dipyridamole-related adverse effects (AEs) during stress myocardial perfusion imaging (MPI)."( Experience of low-dose aminophylline use to relieve minor adverse effects of dipyridamole in patients undergoing stress myocardial perfusion imaging.
Cheng, CY; Hou, CH; Ku, CH; Lin, LF; Shen, DH; Tseng, NC, 2014
)
1
" In this study, we have developed a microfluidic system for phenotype-based evaluation of toxic and teratogenic effects of drugs using zebrafish (Danio rerio) embryos and larvae as the model organism."( Zebrafish on a chip: a novel platform for real-time monitoring of drug-induced developmental toxicity.
Chen, Z; Li, X; Li, Y; Pan, J; Shi, L; Sun, D; Yang, F; Yang, H; Zhang, B, 2014
)
0.4
"Difference in apneic spells, associated respiratory morbidity, and acute adverse events were assessed."( Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial.
Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017
)
0.71
"We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation."( Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.
Autmizguine, J; Bell, C; Christians, U; Cohen-Wolkowieczs, M; Hamilton, KL; Irwin, DC; Klawitter, J; Natoli, MJ; Noveck, RJ; Piantadosi, CA; Schroeder, T, 2018
)
0.74
" On the other hand, the adverse event rates in the caffeine group and the aminophylline group were 70."( [Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants].
Kamimura, H; Nagasato, A; Nakamura, M, 2018
)
0.95
" The primary outcome measures were the efficacy of aminophylline treatment and adverse reactions observed upon administration."( Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit.
Dong, Z; Lu, X; Lyu, Q; Mao, Y; Miao, C; Ye, C; Yu, L; Zhang, J, 2019
)
1.03
"73%) infants had adverse reactions."( Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit.
Dong, Z; Lu, X; Lyu, Q; Mao, Y; Miao, C; Ye, C; Yu, L; Zhang, J, 2019
)
0.77
" Monitoring of serum theophylline concentration should be implemented in the absence of clinical response or in case of suspected adverse reactions."( Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit.
Dong, Z; Lu, X; Lyu, Q; Mao, Y; Miao, C; Ye, C; Yu, L; Zhang, J, 2019
)
0.77
"Reversal of regadenoson with aminophylline is safe and equivalent to adenosine for FFR measurements."( Intravenous regadenoson with aminophylline reversal is safe and equivalent to intravenous adenosine infusion for fractional flow reserve measurements.
Bober, R; Edward, JA; Lee, JH; Morin, DP; White, CJ, 2018
)
1.06
"Utilizing electronic medical records at the University of Colorado hospital, we identified patients ≥ 18 years of age who had a pharmacologic stress test using regadenoson during periods of aminophylline shortage (3/1/2013 to 5/31/2013 and 4/1/2018 to 8/30/2018) in which theophylline was used as an alternative antidote for side effect reversal."( Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal.
Page, RL; Pham, VA; Quaife, RA; Raines, J; Shakowski, C, 2023
)
1.1
" No adverse effects or events were reported."( Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal.
Page, RL; Pham, VA; Quaife, RA; Raines, J; Shakowski, C, 2023
)
0.91
"Due to limited availability of aminophylline, theophylline may be a safe and effective alternative to reverse regadenoson-associated side effects."( Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal.
Page, RL; Pham, VA; Quaife, RA; Raines, J; Shakowski, C, 2023
)
1.2

Pharmacokinetics

Theophylline clearance rates and half-life values were measured in 15 infants aged three to 23 months. The results indicate that, from a metabolic and pharmacokinetic viewpoint, aminophyllines are not equivalent.

ExcerptReferenceRelevance
"Theophylline clearance rates and half-life values were measured in 15 infants aged three to 23 months, after infusion of aminophylline by the intravenous route for at least 24 hours."( Pharmacokinetics of theophylline in infancy.
Simons, FE; Simons, KJ, 1978
)
0.47
"The effect of Chinese herbal medicines (Huan Shao Tan and Pu Chung Yi Chi Tang) and western drugs (sodium phenobarbital and cimetidine) on the serum concentration and pharmacokinetic parameters of theophylline and cytochrome P-450 of Sprague-Dawley (SD) rats of three different ages were examined."( Effect of traditional Chinese herbal medicines on the pharmacokinetics of western drugs in Sprague-Dawley rats of different ages (II): Aminophylline-huan shao tan and aminophylline-pu chung yi chi tang.
Chen, SM; Hou, SJ; Lin, SY; Perng, RI; Young, TK, 1992
)
0.49
" The pharmacokinetic parameters of the two drugs were estimated by model-independent methods."( Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats.
Apichartpichean, R; Hasegawa, T; Muraoka, I; Nabeshima, T; Nadai, M; Takagi, K, 1991
)
0.28
" Time concentration curve of serum theophylline with the three formulations after single and multiple dosage schedules revealed significantly retarded absorption with the SR preparation."( Pharmacokinetics of sustained release and conventional tablets of theophylline plus hydroxyethyltheophylline and its comparison with tablet aminophylline.
Gupta, KL; Gupta, S; Raina, RK; Samotra, K,
)
0.33
" The serum concentrations and pharmacokinetic parameters of theophylline were estimated by a two-compartment open model."( Effect of traditional Chinese herbal medicines on the pharmacokinetics of western drugs in SD rats of different ages. I. Aminophylline-Tin chuan Tang and aminophylline-Hsiao Ching Long Tang.
Chen, SM; Hou, SJ; Lin, SY; Wu, WH; Young, TK, 1991
)
0.49
"Theophylline pharmacokinetic parameters were compared in healthy males and healthy premenopausal females who were matched for age and smoking status."( Sex-related differences in theophylline pharmacokinetics.
Bertino, JS; Nafziger, AN, 1989
)
0.28
"The disposition of theophylline in healthy ruminating calves was best described by a first-order 2-compartment open pharmacokinetic model."( Pharmacokinetic properties of theophylline given intravenously and orally to ruminating calves.
Davis, LE; Koritz, GD; Langston, VC; Neff-Davis, C, 1989
)
0.28
"3 years) were administered aminophylline, 5 mg/kg, before and after a 6-day course of norfloxacin, 400 mg every 12 hours, and changes in pharmacokinetic parameters were measured and compared."( Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.
Dales, RE; Ho, G; Tierney, MG, 1988
)
0.57
" The aim of this study is to determine the pharmacokinetic parameters of vephylline after intravenous and oral (in solution and in tablets) administration to rabbits."( Pharmacokinetics of vephylline--a new N-substituted theophylline derivative.
Astroug, H; Micheva, M; Mihailova, D; Prodanova, K; Staneva, D, 1988
)
0.27
" Model-dependent and model-independent pharmacokinetic parameters for theophylline were compared on the basis of the solvent used in the dosage form administered."( Effect of organic vehicles on the pharmacokinetics of aminophylline administered intravenously to goats.
Bevill, RF; Davis, LE; Koritz, GD; Langston, VC; Munsiff, IJ; Neff-Davis, CA; Sharma, GC, 1987
)
0.52
" The results indicate that, from a metabolic and pharmacokinetic viewpoint, aminophylline and theophylline are not equivalent."( A metabolic and pharmacokinetic comparison of theophylline and aminophylline (theophylline ethylenediamine).
Caldwell, J; Monks, TJ; Smith, RL, 1981
)
0.73
" The following mean pharmacokinetic values were determined; elimination half-life = 11."( Pharmacokinetic disposition of theophylline in horses after intravenous administration.
Beech, J; Kowalczyk, DF; Littlejohn, D, 1984
)
0.27
"A comparative pharmacokinetic study between a sustained-release theophylline tablet (Theona) and aminophylline powder following multiple oral administrations every 12 h at a 200 mg theophylline dose was performed in ten healthy adult volunteers."( Pharmacokinetics of a sustained-release theophylline preparation in healthy subjects.
Goto, M; Nakamoto, Y; Sugiyama, M; Yamashina, H, 1983
)
0.48
"To reach and maintain therapeutic drug concentrations, reliable estimates of the parameters describing the pharmacokinetic behavior of the drug are required."( Optimization of pharmacokinetic monitoring: I. Linear pharmacokinetics.
Berg, MJ; Clarke, MI; Lantz, RK; Schoenwald, RD; Schottelius, DD, 1983
)
0.27
" Pharmacokinetic studies are undertaken with two theophylline formulations commercially available and the commonly used aminophylline to achieve the optimal therapeutic benefit."( [Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations].
Iwainsky, H; Sehrt, I; Wiesner, B, 1984
)
0.48
" This phenomenon could be explained by the finding of a significantly prolonged half-life of theophylline during night-time, provided that the plasma concentrations were in the range of 5 to 15 mg X l-1 (which coincides approximately with the therapeutic range of the drug)."( Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.
Balant, LP; Holtkamp, A; Jonkman, JH; Schoenmaker, R; van der Boon, WJ, 1984
)
0.27
"05 in Ka, tmax and Cmax compared to sustained-release tablets)."( Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
Chiba, K; Echizen, H; Horai, Y; Ishizaki, T; Ohnishi, A; Sasaki, T; Suganuma, T, 1983
)
0.27
" Statistical analysis showed that probenecid had no significant effect on any of the pharmacokinetic parameters measured."( Effect of probenecid on the pharmacokinetics of aminophylline.
Chen, TW; Patton, TF, 1983
)
0.52
" A two-compartment open model was found to describe the decline in the serum concentrations, giving a mean distribution half-life of 6 min."( Pharmacokinetics of proxyphylline in adults after intravenous and oral administration.
Selvig, K, 1981
)
0.26
" No significant difference was found in the pharmacokinetic parameters or protein binding with the two preparations."( Comparative pharmacokinetics of theophylline and aminophylline in man.
Aslaksen, A; Bakke, OM; Vigander, T, 1981
)
0.52
"A pharmacokinetic method of establishing individualized doses of aminophylline in patients with acute bronchospasm was evaluated."( Use of a pharmacokinetic method for establishing doses of aminophylline to treat acute bronchospasm.
Davies, S; Pancorbo, S; Raymond, JL, 1981
)
0.74
"3 ml/kg/h), plasma theophylline half-life (4."( A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission.
Arnold, JD; Hill, GN; Sansom, LN, 1981
)
0.26
"4 years) into a 36-hour, multiple-dose, oral theophylline pharmacokinetic study using plain aminophylline tablets at a dosage of 5 mg of theophylline base/kg every 8 hours."( Theophylline pharmacokinetics in Thai children.
Aranyanark, N; Tuchinda, M; Vichyanond, P; Visitsuntorn, N, 1994
)
0.51
" Neither the serum concentrations nor the pharmacokinetic parameters of sodium valproate (SV) were altered by the coadministration of aminophylline (AMP)."( Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers.
David, J; Joseph, T; Kulkarni, C; Vaz, J, 1995
)
1.94
"Michaelis-Menten pharmacokinetic parameters for theophylline were estimated in a three-month infant following an accidental overdose of intravenous aminophylline."( Aspects of theophylline clearance in children.
Anderson, BJ; Holford, NH; Woollard, GA, 1997
)
0.5
" The purpose of this study was to compare the pharmacokinetic parameters of theophylline and caffeine after intravenous administration of aminophylline to seven Korean low-birthweight neonates with apnea to those in other countries."( Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea.
Ahn, HW; Choi, JH; Park, KJ; Shin, WG; Suh, OK, 1999
)
0.73
" The following results were obtained: 1) Pharmacokinetic parameters of plasma theophylline after an intravenous bolus injection were close to those after the dosing of aminophylline in dogs by a crossover method."( Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine.
Kawai, H; Kojima, J; Kokubun, S; Matsumoto, T; Onodera, K, 2000
)
0.5
"The present work aimed to estimate the theophylline pharmacokinetic parameters (TH-PKP) in preterm neonates with apnea during the first month of life in order to optimize its dosage regimen."( Pharmacokinetics of theophylline in preterm neonates during the first month of life.
Ali, AS; Fida, NM; Islam, SI; Sheikh, AA, 2004
)
0.32
"Phenobarbital significantly enhanced TH clearance (CL) and reduced its half-life (t0."( Pharmacokinetics of theophylline in preterm neonates during the first month of life.
Ali, AS; Fida, NM; Islam, SI; Sheikh, AA, 2004
)
0.32
" To evaluate pharmacokinetic characteristics of interaction between topiramate and aminophylline, total brain concentrations of topiramate and theophylline were estimated with fluorescence polarization immunoassay technique."( Pharmacokinetic and pharmacodynamic interactions of aminophylline and topiramate in the mouse maximal electroshock-induced seizure model.
Czuczwar, SJ; Jankiewicz, K; Jankiewicz, M; Luszczki, JJ, 2007
)
0.82
" However this correlation was found only in a very narrow range of concentrations of TP, and pharmacokinetic analysis of TP in tears has not been carried out for a wide range of concentrations of TP."( Pharmacokinetics of theophylline in Guinea pig tears.
Honda, A; Konishi, T; Miyazaki, H; Nakajima, M; Sato, S, 2007
)
0.34
" Serum concentrations were analysed over a period of 6 h and pharmacokinetic key variables for each drug were calculated."( Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs.
Aadahl, P; Aasarød, K; Asheim, P; Spigset, O; Uggen, PE; Walstad, RA; Zahlsen, K, 2008
)
0.6
"The pharmacokinetic properties after intraperitoneal administration differed among the three drugs, but the results are encouraging and provide a basis for further investigation in humans."( Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs.
Aadahl, P; Aasarød, K; Asheim, P; Spigset, O; Uggen, PE; Walstad, RA; Zahlsen, K, 2008
)
0.6
"The pharmacokinetic study indicated that the usage of a sustained-release formula should not usually be over 15 mg/ml, but the additional use of an aminophylline suppository elevated the concentration to over 20 mg/ml and resulted in the severe adverse effects."( Theophylline-associated status epilepticus in an infant: pharmacokinetics and the risk of suppository use.
Kato, Z; Kondo, N; Nakamura, M; Yamagishi, A, 2009
)
0.55
" The pharmacokinetic parameters of aminophylline were calculated and population pharmacokinetic model was established by MW/Pharm3."( [Investigation on pharmacokinetics of aminophylline in very low birth weight infants].
Chen, DP; Mu, DZ; Shi, J; Tang, J; Wu, JL; Xiong, Y, 2013
)
0.94
"This study aimed to characterize pharmacodynamic interaction between propofol and aminophylline."( Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs.
Choi, BM; Choi, YJ; Jin, SJ; Kang, HJ; Lee, EK; Lee, SH; Noh, GJ; Park, DY, 2014
)
1.03
"To study the pharmacokinetic and pharmacodynamic features of different doses of aminophylline in very low birth weight (VLBW) infants with different postmenstrual ages, weights, and ages (in days)."( [Investigation of pharmacokinetics and pharmacodynamics of different doses of aminophylline in very low birth weight infants].
Chen, DP; Mu, DZ; Shi, J; Tang, J; Wu, JL; Xiong, Y; Yang, XY; Zhao, J, 2015
)
0.87
" Pharmacokinetic data of aminophylline were compared between the two groups."( [Investigation of pharmacokinetics and pharmacodynamics of different doses of aminophylline in very low birth weight infants].
Chen, DP; Mu, DZ; Shi, J; Tang, J; Wu, JL; Xiong, Y; Yang, XY; Zhao, J, 2015
)
0.95
" To help understand optimal aminophylline (salt formulation of theophylline) dosing strategies in this population, a population-based pharmacokinetic model was developed using nonlinear mixed-effects modeling (NONMEM) from 71 children (median age 5 months; 90% range 1 week to 10 years) who underwent cardiac surgery requiring CPB and received aminophylline as part of a previous randomized controlled trial."( Theophylline Population Pharmacokinetics and Dosing in Children Following Congenital Heart Surgery With Cardiopulmonary Bypass.
Axelrod, DM; Frymoyer, A; Grimm, PC; Su, F; Sutherland, SM, 2016
)
0.73
"To evaluate physiologically based pharmacokinetic modelling (PBPK) software in paediatric asthma patients using intravenous aminophylline."( Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations.
Cooney, L; Hawcutt, DB; Johnson, TN; Lilley, A; McBride, A; Sinha, I, 2017
)
0.89
" Non-compartment pharmacokinetic analysis was used to estimate pharmacokinetic parameters."( Effect of aminophylline on the pharmacokinetics of amikacin in Sprague-Dawley rats.
Amponsah, SK; Antwi, KA; Kunkpeh, VP; Opuni, KF, 2019
)
0.92
"A population pharmacokinetic analysis was performed in 22 neonates with HIE undergoing hypothermia who were part of a prospective study or retrospective chart review."( Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Chock, VY; Christians, U; Drover, DR; Frymoyer, A; Klawitter, J; Van Meurs, KP, 2020
)
0.56
" The median half-life was 39."( Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Chock, VY; Christians, U; Drover, DR; Frymoyer, A; Klawitter, J; Van Meurs, KP, 2020
)
0.56
"In neonates with HIE undergoing hypothermia, theophylline clearance was low with a 50% longer half-life compared to full-term normothermic neonates without HIE."( Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Chock, VY; Christians, U; Drover, DR; Frymoyer, A; Klawitter, J; Van Meurs, KP, 2020
)
0.56
" Theophylline clearance was low in neonates with HIE undergoing therapeutic hypothermia with a 50% longer half-life compared to full-term normothermic neonates without HIE."( Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Chock, VY; Christians, U; Drover, DR; Frymoyer, A; Klawitter, J; Van Meurs, KP, 2020
)
0.56

Compound-Compound Interactions

Aminophylline and beclomethasone combined with enteral nutrition in the treatment of elderly patients with chronic obstructive pulmonary disease (COPD) The study also looked at the effects of these drugs on patient nutritional status.

ExcerptReferenceRelevance
"Effects of flutropium bromide, a new bronchodilator with an anticholinergic action, alone or in combination with other antiasthma drugs were investigated in guinea pigs by using an index of inhibition of the acetylcholine (ACh)-induced bronchoconstriction."( [Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction].
Misawa, M; Mizuno, H; Ohno, H; Takahashi, Y, 1990
)
0.5
"It has been demonstrated in experiments on normotensive cats that during chronic administration of spironolactone alone or combined with euphylline there occur inconclusive variations in the transmural potential difference and electrolyte balance in the vascular wall."( [Changes in the electrolyte balance and the transmural differential in the potentials of the blood vessel wall during the administration of spironolactone and its combination with euphylline].
Erikov, VM,
)
0.13
"2 mg/kg) combined with aminophylline in cardiopulmonary resuscitation (CPR)."( [Study on the value of the formula of rapid synchronous stepwise increase in dosage of epinephrine combined with aminophylline (7 mg/kg) in cardiopulmonary resuscitation].
Huang, X; Jiang, FZ; Shi, QB; Wang, GE; Xu, YS; Zhang, FX, 2008
)
0.87
"To investigate the efficacy of beclomethasone and aminophylline combined with enteral nutrition in the treatment of elderly patients with chronic obstructive pulmonary disease (COPD) and the associated effects of these drugs on patient nutritional status and immune function."( Effects of beclomethasone and aminophylline combined with enteral nutrition in chronic obstructive pulmonary disease on nutritional status and immune function in elders.
Chen, H; Li, H; Peng, C; Rao, L; Xiao, D; Xiao, H, 2021
)
1.16
" Aminophylline, in combination with beclomethasone, was administered to the CON group, whereas aminophylline and beclomethasone in combination with EN was administered to the EN group."( Effects of beclomethasone and aminophylline combined with enteral nutrition in chronic obstructive pulmonary disease on nutritional status and immune function in elders.
Chen, H; Li, H; Peng, C; Rao, L; Xiao, D; Xiao, H, 2021
)
1.82
"To explore the application effect of aminophylline combined with caffeine citrate and GMs in the evaluation of neurodevelopmental treatment and follow-up in high-risk preterm infants."( Aminophylline in combination with caffeine citrate in neurodevelopmental treatment and follow-up of high-risk preterm infants using GMs assessment.
Chen, W; Feng, X; Zheng, K, 2022
)
2.44

Bioavailability

The absolute bioavailability of a new aminophylline sustained-release formulation (BY108) was determined in a single-dose bioavailability study. The bioavailability and in vitro release rates were correlated with in vitro dissolution results by moment analysis.

ExcerptReferenceRelevance
" A possible explanation for the observed difference in response between the two groups may have been variation in bioavailability of aminophylline in the two clinical situations."( Effect of slow-release oral aminophylline on circadian variation in airflow obstruction in asthmatics.
Al-Khader, A; Cole, RB, 1979
)
0.76
" The qualities of both drugs as to their bioavailability and effect on airway obstruction shall be examined by means of another comparative study."( [Comparative examination of theophylline-serum-concentrations and bronchospasmolytic effect of cholintheophyllinate (euspirax) and theophyllin-aethylendiamine (euphyllin retard) in patients with obstructive airway diseases (author's transl)].
Oellerich, M; Schnitker, J; Wettengel, R, 1979
)
0.26
"The bioavailability of a rapidly dissolving tablet of theophylline and three brands of standard aminophylline tablets was estimated in a four way cross-over study involving 8 healthy adult volunteers."( Comparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tablets.
Cooper, D; Milne, RW; Sansom, LN, 1979
)
0.7
" Accumulation of caffeine, with its subsequent metabolism to theophylline, in patients, who consume average quantities of caffeine-containing beverages relative to those patients who avoid such drinks could interfere with bioavailability studies in normal volunteers."( The human metabolism of caffeine to theophylline.
Hossie, RD; McGilveray, IJ; Sved, S, 1976
)
0.26
" The bioavailability of these two aminophylline SR tablets was also evaluated in eight healthy male Chinese volunteers and correlated with in vitro dissolution results by moment analysis."( Preliminary evaluation of the correlation between in vitro release and in vivo bioavailability of two aminophylline slow-release tablets.
Chang, HN; Kao, YH; Lin, SY, 1990
)
0.77
" Absolute bioavailability was 87% for the immediate-release and 97% for the sustained-release formulation."( Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse.
Goetz, TE; McKiernan, BC; Munsiff, IJ, 1989
)
0.53
"The effect of differing fat contents of food on the bioavailability of theophylline following a 400-mg single dose of Theo-24 was studied in mini-swine."( The effect of food on the absorption of controlled-release theophylline in mini-swine.
Prasad, VK; Sager, AO; Shiu, GK; Skelly, JP; Velagapudi, RB, 1988
)
0.27
" After oral administration of the drug in solution the absorption half-life is short and the bioavailability is relatively high."( Pharmacokinetics of vephylline--a new N-substituted theophylline derivative.
Astroug, H; Micheva, M; Mihailova, D; Prodanova, K; Staneva, D, 1988
)
0.27
"The effect of different intravenous infusions on the absolute bioavailability of theophylline from a sustained-release formulation has been investigated."( Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions.
Beier, W; Böhm, A; Schulz, HU; Steinijans, VW, 1987
)
0.27
" The present study also showed that the formulation was good sustained-release properties with adequate bioavailability and that the in vitro sustained-release characteristic was confirmed to be reflected in the plasma concentration-time profile of theophylline in the in vivo."( Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
Hasegawa, T; Imaeda, N; Mizukami, Y; Ogura, Y; Satake, T; Suzuki, R; Takagi, K; Yamaki, K, 1987
)
0.27
"Absorption of theophylline from one commercial product labelled as aminophylline sustained release was compared to the absorption from an oral solution of aminophylline in a single-dose bioavailability study."( [Bioavailability of a delayed-action aminophylline preparation].
Bartoli, A; Ciardelli, L; Guarnone, E; Piacentini, P; Regazzi, MB, 1985
)
0.78
"This study was undertaken to compare the bioavailability and the in vitro release rates of theophylline from suppositories containing either theophylline or aminophylline."( Theophylline versus aminophylline in rectal administration.
Touitou, E; Yosselson-Superstine, S, 1985
)
0.79
"The pharmacokinetics and bioavailability of theophylline in horses were investigated following both intravenous and intragastric administration of aminophylline solutions at doses corresponding to 15 and 10 mg/kg theophylline base."( Pharmacokinetics and bioavailability of theophylline in horses.
Baggot, JD; Button, C; Errecalde, JO; Mulders, MS, 1984
)
0.47
"The absolute bioavailability of a new aminophylline sustained-release formulation (BY108) was determined."( Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Fischer, R; Steinijans, VW; Zech, K, 1983
)
0.9
" Regarding the results Aminophylline retard belongs to the formulations with diminished bioavailability and is therefore not satisfactorily qualified for an optimal treatment."( [Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations].
Iwainsky, H; Sehrt, I; Wiesner, B, 1984
)
0.58
" This finding indicates complete bioavailability of the sustained release tablets on both occasions."( Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.
Balant, LP; Holtkamp, A; Jonkman, JH; Schoenmaker, R; van der Boon, WJ, 1984
)
0.27
"The bioavailability and pharmacokinetics of theophylline from a plain uncoated and 2 newly designed, sustained-release tablet formulations, as compared to intravenous aminophylline, were studied in 12 healthy adult male volunteers."( Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
Chiba, K; Echizen, H; Horai, Y; Ishizaki, T; Ohnishi, A; Sasaki, T; Suganuma, T, 1983
)
0.46
" These data suggest that verapamil, and partially amrinone, inhibit histamine-induced tracheal contractions by reducing the bioavailability of intracellular Ca2+."( Relaxant effects of amrinone upon pulmonary smooth muscle.
Buck, DC; Mielens, ZE, 1982
)
0.26
"The absolute bioavailability of theophylline in two commercially available preparations of aminophylline, a sustained-release formulation (Euphyllin retard tablets) and a solution (Euphyllin solution), was determined in eight healthy volunteers following oral administration of a single dose."( Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Molz, KH; Rietbrock, N; Schuppan, D; Staib, AH, 1981
)
0.73
" In this study, no difference was demonstrated in the apparent clearance rate (Clapp), apparent first-order absorption rate constant (ka), maximum serum drug concentration (Cmax), time of maximum drug concentration (Tmax) or absorption lag time (tlag) for theophylline before and after treatment with erythromycin."( The effects of erythromycin on the absorption and disposition of kinetics of theophylline.
Branigan, TA; Cady, WJ; Nickols, JG; Robbins, RA; Ueda, CT, 1981
)
0.26
"This study evaluated the relative bioavailability of a sustained-release capsule of theophylline, an elixir of theophylline, and a sustained-release tablet of aminophylline."( A multiple-dose study of sustained-release theophylline and aminophylline.
Lieberman, P; Meyer, MC; Straughn, AB, 1980
)
0.7
"A two-way complete crossover bioavailability study of solutions of theophylline given orally or rectally in 16 healthy subjects was conducted."( Bioavailability of theophylline following a rectally administered concentrated aminophylline solution.
Amick, EN; Arnold, J; Lanman, RC; March, L; Mason, WD, 1980
)
0.49
" Bioavailability of CBZ was reduced by 29% in the presence of AMP, while that of SV was increased by about 8%."( Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers.
David, J; Joseph, T; Kulkarni, C; Vaz, J, 1995
)
1.73
" However, considering the time consuming and expensive in vivo tests, quantitative correlation between in vivo bioavailability and in vitro dissolution tests can be used routinely in quality control tests of these drug products to predict the in vivo pharmacokinetic parameters."( Biopharmaceutical characterization of oral theophylline and aminophylline tablets. Quantitative correlation between dissolution and bioavailability studies.
Falamarzian, M; Ghafghazi, T; Raisi, A; Varshosaz, J, 2000
)
0.55
" The bioavailability of the compound following the colon administration in dogs, relative to the same formulation administered orally (relative bioavailability), was determined."( Dog colonoscopy model for predicting human colon absorption.
Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006
)
0.33
"Except for atenolol, a small hydrophillic molecule, the relative bioavailability from administration to the colon of the dog correlated well with the following compound properties: high solubility and high, passive permeability > high solubility, low permeability > low solubility, high, passive permeability approximately low solubility, low permeability."( Dog colonoscopy model for predicting human colon absorption.
Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006
)
0.33
" However, no human intubation or dog colon studies are required for Class 1 (HS/HP), as these compounds are likely to be well absorbed from the colon."( Dog colonoscopy model for predicting human colon absorption.
Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006
)
0.33
" The absolute bioavailability (F) after oral administration was (83."( Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens.
Li, J; Liu, F; Sui, C; Wan, RZ; Wan, SJ; Wang, SL; Yan, SY; Yin, B, 2016
)
0.69
" These findings suggest that the OFT is well absorbed and can likely be dosed twice daily in dogs, but future pharmacodynamic and clinical studies are needed to establish a definitive therapeutic range for theophylline in this species."( Pharmacokinetics of a 503B outsourcing facility-produced theophylline in dogs.
de Oliveira, GAR; Forsythe, L; Li, Z; Reinhart, JM, 2022
)
0.72

Dosage Studied

Aminophylline inhibits adenosine receptors, exerts beneficial effect on exercise induced ischemia in syndrome X. Study compared effects of high-dose and low-dose aminophyllines on lung function of animals with MAS.

ExcerptRelevanceReference
" Dose-response data were obtained and ED50 values for pulmonary and cardiovascular blockade were compared."( Differences in pulmonary and cardiovascular beta receptors in the guinea pig and rabbit.
Alvarez, R; Bradshaw, J; Marian, J; Weissberg, RM, 1977
)
0.26
" The dosage of Phyllocontin tablets used was 12."( Monitoring response to bronchodilator therapy in asthma in childhood.
Macdonald, TH; McWilliam, R, 1979
)
0.26
" Adenosine inhibited the Ca2+ dose-response curves of strips stimulated with 20 mM and 30 mM K+ and its effect was dependent on the Ca2+ concentration."( Adenosine relaxation of isolated vascular smooth muscle.
Berne, RM; Bockman, EL; Herlihy, JT; Rubio, R, 1976
)
0.26
" Based on a dose-response analysis, 1-methyl-3-isobutylxanthine was 200 times more potent than aminophylline."( Insect prothoracic glands: a role for cyclic AMP in the stimulation of alpha-ecdysone secretion.
Bollenbacher, WE; Gilbert, LI; Vedeckis, WV,
)
0.35
" To evaluate this possibility, the authors devised a technique for determining the minimal arrhythmic dosage of epinephrine that permitted graded assessment of changes in the sensitivity of the heart to epinephrine-induced arrhythmias."( Effects of pharmacologic alterations of adrenergic mechanisms by cocaine, tropolone, aminophylline, and ketamine on epinephrine-induced arrhythmias during halothane-nitrous oxide anesthesia.
Koehntop, DE; Liao, JC; Van Bergen, FH, 1977
)
0.48
" The histamine respiratory dose-response curve was shifted to the left in the presence of the phosphodiesterase inhibitor aminophylline."( Potentiation by carbachol and aminophylline of histamine- and db-cAMP-induced parietal cell activity in isolated gastric glands.
Berglindh, T, 1977
)
0.75
" Statistical tests of parallelism revealed a significant difference between the log dose-response curves of Sch 15280 and ephedrine but not between those of Sch 15280, atropine and aminophylline."( Experimental study of a potential anti-asthmatic agent: SCH 15280.
Adams, GK; Bleidt, B; Diamond, L; Williams, B, 1975
)
0.45
" The dosage of Phyllocontin tablets was adjusted in a pre-trial study to provide serum theophylline levels in the accepted therapeutic range of 10--20 mg/l."( A double-blind trial of oral aminophylline (Phyllocontin Continus tablets) in airflow obstruction: preliminary communication.
Baillie, E; Greening, AP; Gribbin, HR; Pride, NB, 1979
)
0.55
" The shape of the salbutamol dose-response curve was not altered by aminophylline pre-treatment--it is therefore argued that the drugs are additive but not synergistic on the basis of this preliminary study."( Additive interaction of aminophylline and salbutamol in asthma: an in vivo study using dose-response curves.
Handslip, P; Leopold, D, 1979
)
0.8
" When initiating continuous oral aminophylline therapy, dosage guidelines, based on the mean ATC calculated for each group, were predicted, and trough theophylline serum levels of 10mug/ml were obtained."( Oral aminophylline therapy. Increased dosage requirements in children.
Austrian, S; Johnson, PB; Miller, KW; Strem, EL; Zaske, DE, 1977
)
1.05
"9 mg/kg/hr to a maximum dosage of 1,500 mg/24 hr."( Theophylline concentrations in asthmatic patients after administration of aminophylline.
Kordash, TR; McCall, JT; Van Dellen, RG, 1977
)
0.49
" Following intensive round-the-clock therapy with theophylline (the dosage of which maintained serum levels of theophylline between 10 microgram/ml and 20 microgram/ml) and therapy with prednisone (20 mg twice daily for three weeks or more), there were improvements in spirometric and body plethysmographic measurements."( Irreversibility of obstructive changes in severe asthma in childhood.
Bell, TD; Buck, VM; Chai, H; Cooley, RL; Leung, PK; Loren, ML, 1978
)
0.26
" An increased dosage of aminophylline produced unacceptably high maternal tachycardia."( Uterine and cardiovascular effects of aminophylline.
Lipshitz, J, 1978
)
0.84
"A new kinetically based dissolution equation is presented that considers dissolution of polydisperse systems and disintegrating solid dosage forms."( Versatile kinetic-approach to analysis of dissolution data.
Myrick, JW; Pedersen, PV, 1978
)
0.26
"Minophylline (theophylline ethanoate of piperazine) and aminophylline (theophylline ethylenediamine) were determined spectrophotometrically in dosage forms without interference from excipients and/or preservatives."( Spectrophotometric determination of theophylline formulations.
Abdine, H; Elsayed, MA; Elsayed, YM, 1979
)
0.51
"Predicted and approximated mean serum theophylline concentrations were compared to assess the feasibility of using theophylline clearance, calculated from the intravenous steady-state serum theophylline concentration, to determine appropriate oral dosage requirements."( Reliability of theophylline clearance in determining chronic oral dosage regimens.
Grambau, G; Johnson, CE; Slotfeldt, ML; Weg, JG, 1979
)
0.26
" Results as well as specific dosage problems are discussed."( [Euphylline suppositories in the treatment of obstructive respiratory tract diseases in childhood].
Saule, H, 1976
)
0.26
" This plateau can be maintained and is dependent upon dosage and the half-life of theophylline, which varies amongst individuals."( [Theophylline blood levels after administration of Euphyllin retard (author's transl)].
Ahrens, J, 1977
)
0.26
" These complications may necessitate diminishing the dosage of the medications."( Aminophylline and isoproterenol in the treatment of cerebral vasopasm.
Fleischer, AS; Raggio, JF; Tindall, GT, 1977
)
1.7
" Fusaric acid produced a shift to the right and down in the dose-response curves to all tested agonists, and antagonized acetylcholine and serotonin most effectively among these agonists."( Relaxation of isolated rabbit arteries by fusaric (5-butylpicolinic) acid.
Asano, M; Hidaka, H, 1976
)
0.26
" In addition, the effect on the norepinephrine dose-response curve of the combination of a methyixanthine and U-0521,the latter a potent inhibitor of catechol O-methyltransferase, the major enzyme of catecholamine inactivation in vascular tissue, did not differ from that of U-0521 alone."( Mechanism of methylxanthine sensitization of norepinephrine responses in a coronaryartery.
Frew, RD; Kalsner, S; Smith, GM, 1975
)
0.25
" Dose-response curves of isoproterenol were shifted significantly to the left by 2 x 10(-5) M aminophylline."( Comparison of the relaxing effect of dopamine with that of adenosine, isoproterenol and acetylcholine in isolated canine coronary arteries.
Hojo, M; Sakae, K; Toda, N; Usui, H, 1975
)
0.47
" The results were opposite to other studies, probably because the dose and dosing intervals were different."( Effect of traditional Chinese herbal medicines on the pharmacokinetics of western drugs in Sprague-Dawley rats of different ages (II): Aminophylline-huan shao tan and aminophylline-pu chung yi chi tang.
Chen, SM; Hou, SJ; Lin, SY; Perng, RI; Young, TK, 1992
)
0.49
" The careful monitoring of serum theophylline level and modification of theophylline dosage in patients receiving enoxacin and theophylline were recommended."( [Effect of enoxacin on theophylline pharmacokinetics].
Liu, YN, 1992
)
0.28
" Measurement of serum concentrations of theophylline should be employed to facilitate increases in dosage during hemodialysis."( Clearance of theophylline by hemodialysis in one patient with chronic renal failure.
Chang, DB; Kuo, SH; Luh, KT; Shen, FH; Yang, PC, 1992
)
0.28
" Using area under the curve and half-life calculations it was determined that each of the dosage regimens significantly reduced the reabsorption of theophylline and the plasma half-life when compared with control."( The comparative efficacy of various multiple-dose activated charcoal regimens.
Ilkhanipour, K; Krenzelok, EP; Yealy, DM, 1992
)
0.28
"In order to test the GABA hypothesis of kindling, GABA-complex antagonists were administered in a dose-response paradigm to rats that had been implanted with indwelling forebrain electrodes, but not kindled."( Secondary generalization in non-kindled rats following acute administration of GABA-complex and adenosine antagonists.
Burnham, WM; Mingo, NS, 1990
)
0.28
" Total cumulative amounts of furosemide, chlorothiazide, spironolactone accrued during hospitalization (dosage per patient per day), and a diuretic index (logarithm of the sum of the cumulative dosage of the three diuretics) were calculated for each patient."( Diuretics, hypochloremia, and outcome in bronchopulmonary dysplasia patients.
Giacoia, GP; Pineda, R, 1991
)
0.28
" Time concentration curve of serum theophylline with the three formulations after single and multiple dosage schedules revealed significantly retarded absorption with the SR preparation."( Pharmacokinetics of sustained release and conventional tablets of theophylline plus hydroxyethyltheophylline and its comparison with tablet aminophylline.
Gupta, KL; Gupta, S; Raina, RK; Samotra, K,
)
0.33
" The following observations were made: four patients had sinus tachycardia and another suffered from ventricular extrasystoles as seen in the electrocardiographic register; another two patients had sinus tachycardia when the bronchial dilator dosage was doubled."( [Electrocardiographic changes with the use of aminophylline and salbutamol in adult patients with chronic bronchial asthma].
Esquer Flores, J; Gálvez Gudiño, VJ; Orea Solano, M,
)
0.39
" The experimental protocol utilized a computer-assisted dosage prediction program that incorporated baseline theophylline concentration rapidly obtained using a bedside assay."( Aminophylline in the emergency department. Maximizing safety and efficacy.
Day, RO; Fulde, GW; Kino, R; Pearce, GA, 1991
)
1.72
"Theophylline concentrations in serum between 10 to 20 micrograms/ml cannot be obtained with usual dosage of theophylline in children with individual very short elimination half time of theophylline."( [Individually-adjusted dosages of aminophylline in children with bronchial asthma].
Feller, K; Gramatté, T; Leupold, W; Paditz, E; Richter, K, 1990
)
0.56
" If these data apply to humans, B6 deficiency may contribute to chronic theophylline toxicity; however, pyridoxine administration in the dosage used may not prevent toxicity."( Depression of vitamin B6 levels due to theophylline.
Enriquez, JI; Keniston, RC; McNamee, GA; Weir, MR, 1990
)
0.28
" We determined the inhaled adenosine dose-response curves after no treatment and after treatment with aminophylline (240 mg in 10 min), reproterol (90 mcg in 2 min) and salbutamol (100 mcg in 2 min) administered intravenously 15 min before adenosine and reproterol (500 mcg) and salbutamol (200 mcg) administered by inhalation from a metered aerosol 30 min before adenosine on separate days."( Role of purinergic system in tracheobronchial reactivity of healthy and bronchopathic subjects.
Carapella, N; Filippelli, A; Loffreda, A; Marmo, E; Matera, MG; Montanaro, C; Santagata, A; Servodio, R; Susanna, V, 1990
)
0.49
" Adenosine decreased the SVR in a dose-related manner at the lower dosage amounts but caused a maximum decrease in SVR at the higher dosage amounts averaging 30% below the Ringer control values."( Vascular development in chick embryos: a possible role for adenosine.
Adair, TH; Guyton, AC; Montani, JP; Strick, DM, 1989
)
0.28
" Methacholine dose-response curves (10(-11) to 10(-7) mol iv) obtained at the conclusion of the experiments were similar among capsaicin, phosphoramidon, and control groups."( Tachykinins mediate bronchoconstriction elicited by isocapnic hyperpnea in guinea pigs.
Drazen, JM; Hernandez, C; Leff, AR; Ray, DW; Solway, J, 1989
)
0.28
" In order to test this hypothesis, IV aminophylline (6 mg/kg over fifteen minutes), a dosage known to effectively block adenosine receptors, was acutely administered--in a double-blind, placebo-controlled study design--in 13 patients with intermittent claudication and documented atherosclerotic disease."( Increase of walking capacity after acute aminophylline administration in intermittent claudication.
Gaudio, V; L'Abbate, A; Lattanzi, F; Picano, E; Pogliani, M; Testa, R, 1989
)
0.81
" The patients were assigned to three groups according to the dosage of aminophylline administered."( [Determination of the optimal dose of aminophylline in children with severe asthmatic attacks].
Ahel, V; Gazdik, M; Rozmanić, V; Zubović, I, 1989
)
0.78
" Evaluation of the change in theophylline level resulting from aminophylline loading doses based on either TBW or IBW revealed that each dosing method produced changes in blood level with similar variability that were not independent of obesity, indicating that neither dosing method is superior to the other."( Aminophylline loading in asthmatic patients: a protocol trial.
Marcus, RH; Parvin, CA; Stine, RJ, 1989
)
1.96
" Thus, at a dosage which effectively inhibits adenosine receptors, aminophylline infusion exerts beneficial effect on exercise induced ischemia in syndrome X, possibly through the prevention of transmural steal phenomena, elicited by inappropriate adenosine release during effort."( [Increase in tolerance to physical effort in patients with X syndrome after acute administration of aminophylline].
Emdin, M; Lattanzi, F; Picano, E,
)
0.58
"The effects of roxatidine acetate hydrochloride and cimetidine during multiple dosing on the pharmacokinetics of theophylline was studied in nine healthy volunteers, five smokers and four non-smokers, in comparison with placebo treatment."( Effects of roxatidine acetate hydrochloride and cimetidine on the pharmacokinetics of theophylline in healthy subjects.
Aoi, R; Ishioka, T; Ogata, H; Takeuchi, H; Yoshimura, N, 1989
)
0.28
" We conclude that aminophylline produces no enhancement of skeletal muscle strength, at therapeutic dosage in normal subjects."( The effect of aminophylline on respiratory and limb muscle contractility in man.
Brophy, C; Green, M; Mier, A; Moxham, J, 1989
)
0.97
" Thus, at a dosage that should effectively inhibit adenosine receptors, aminophylline infusion exerts a beneficial effect on exercise-induced ischemia, possibly through the prevention of myocardial flow maldistribution elicited by excessive adenosine release during effort."( Exercise capacity after acute aminophylline administration in angina pectoris.
Distante, A; L'Abbate, A; Lattanzi, F; Picano, E; Pogliani, M, 1989
)
0.8
" The response was characterized by dose-response and kinetics investigations."( The proliferative T-lymphocyte response to streptokinase.
Bruserud, O; Jørgensen, PF; Sollid, L, 1986
)
0.27
" The dose-response curves for both adenosine and L-PIA were shifted to the right in the presence of aminophylline (13 and 32 mumol l-1)."( [Comparative effects of adenosine and L-N-phenylisopropyladenosine (L-PIA) on the spontaneous contraction of the isolated atrium in the guinea-pig].
Prostran, M; Varagić, VM, 1986
)
0.49
" Dose-response curves were obtained for inhaled salbutamol and inhaled ipratropium bromide."( Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease.
Agusti-Vidal, A; Campistol, J; Lloberes, P; Montserrat, JM; Picado, C; Ramis, L; Serra, J, 1988
)
0.27
"A double-blind crossover study has been performed in 14 patients with moderately severe chronic asthma to compare the bronchodilator efficacy of two dosage regimens of intravenous enprofylline (high dose = 2 mg/kg bolus and 1 mg/kg/hour infusion; low dose = 1 mg/kg bolus and 500 micrograms/kg/hour infusion) with aminophylline (5 mg/kg/bolus and 500 micrograms/kg/hour infusion) and placebo."( Enprofylline in chronic asthma.
Capewell, S; Chapman, BJ; Crompton, GK; Frame, MH; McDonald, C, 1988
)
0.45
" In the presence of a standard concentration of verapamil (73 nmol l-1), the dose-response curves for NECA, both for the isometric contraction and the atrial rate, were significantly shifted to the left."( Interactions of 5'-N-ethylcarboxamide adenosine (NECA), aminophylline and dipropyl-phenyl-xanthine (XAC) on the isolated guinea-pig atria.
Prostran, M; Varagic, VM,
)
0.38
" After 5 days of continuous dosing (at 6 PM), all patients received their regular Uniphyl dose under specified fasting conditions, and serum theophylline concentrations were measured sequentially during the following 24 hours."( The clinical significance of food-induced changes in the absorption of theophylline from Uniphyl tablets.
Aitken, T; Arkinstall, WW; Calcutt, L; Hopkinson, M; Rivington, RN; Stewart, JH, 1988
)
0.27
" The effect of theophyllines on skeletal muscle is dose related and animal studies show that any effect in humans, where dosage is limited by toxicity, is likely to be small."( Aminophylline and the respiratory muscles: an alternative view.
Moxham, J, 1988
)
1.72
" 96 out of 194 (49%) tests were eliminated because of inappropriate sample collection or irrational dosage regimen."( [Importance of the laboratory in optimizing anti-asthma therapy with theophylline].
Snidero, M, 1987
)
0.27
" One hundred ten patients undergoing routine diagnostic upper gastrointestinal endoscopy received diazepam intravenously in a dosage sufficient to achieve adequate sedation."( Low dose aminophylline accelerates recovery from diazepam premedication for digestive endoscopy.
Atkinson, M; Foster, PN; Herbert, M; Moles, EJ; Sheard, C, 1987
)
0.69
" Given these findings, we advise that, for patients who are treated with theophylline and are subsequently treated with norfloxacin, adjustment of the theophylline dosage may be necessary in some patients to minimize the risk of theophylline toxicity."( Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.
Dales, RE; Ho, G; Tierney, MG, 1988
)
0.27
" This disparity reflects the greater bronchodilation effected by isoproterenol as a single agent than by epinephrine, in the dosing schedules and routes of administration chosen."( Treatment of acute asthma. Is combination therapy with sympathomimetics and methylxanthines indicated?
Fanta, CH; McFadden, ER; Rossing, TH, 1986
)
0.27
" With the changes in usage and dosage forms, the frequency of toxicity in the pediatric population, especially in adolescents, has increased dramatically."( Aminophylline toxicity.
Albert, S, 1987
)
1.72
" We conclude that neither time of dosing nor age are important determinants of theophylline elimination kinetics in healthy subjects."( Effects of time of dosing and age on intravenous aminophylline pharmacokinetics.
Bateman, DN; Rodgers, A; Woodhouse, KW, 1987
)
0.53
" Model-dependent and model-independent pharmacokinetic parameters for theophylline were compared on the basis of the solvent used in the dosage form administered."( Effect of organic vehicles on the pharmacokinetics of aminophylline administered intravenously to goats.
Bevill, RF; Davis, LE; Koritz, GD; Langston, VC; Munsiff, IJ; Neff-Davis, CA; Sharma, GC, 1987
)
0.52
" Data were used to plot dose-response curves for the four test compounds."( Adenosine mediates the negative chronotropic action of adenosine 5'-triphosphate in the canine sinus node.
Menduke, H; Michelson, EL; Mitsuoka, T; Pelleg, A, 1987
)
0.27
"To investigate the possible mechanisms by which theophylline affects the control of ventilation, neuromuscular drive and ventilatory function were examined in 7 healthy men receiving an incremental intravenous aminophylline dosing schedule to achieve plasma theophylline concentrations of 5, 10, and 15 micrograms/ml."( Effect of theophylline on respiratory neuromuscular drive.
Ishizaki, T; Konno, K; Kubo, M; Okubo, S; Suganuma, T; Takizawa, T, 1987
)
0.46
" In contrast, on oral dosing a smaller area under the serum concentration-time curve was found during the night time (22."( Circadian changes in the absorption and elimination of theophylline in patients with bronchial obstruction.
Follath, F; Uematsu, T; Vozeh, S, 1986
)
0.27
" These methods provide a rapid means of monitoring dosage in the individual patient."( Early estimate of theophylline clearance during intravenous infusion.
Bonanno, A; Bonsignore, G; Ferrara, G; Mangiacavallo, A; Mirabella, A; Rizzo, A, 1986
)
0.27
" The tested medication has a favorable therapeutic spectrum as a result of the low dosage of the individual substances."( [Bronchospasmolytic effectiveness of controlled drug combinations].
Forche, G; Harnoncourt, K; Zenker, G, 1986
)
0.27
" The dose-response curve for the action of forskolin (2."( The effect of forskolin on the isometric contraction of the isolated hemidiaphragm of the rat.
Prostran, M; Varagić, VM, 1986
)
0.27
" The drug dosage was determined by means of a stepwise increase of a daily dose in the range of 10-30 mg/kg/day under control of the patient's general condition and parameters of external respiratory function."( [Theophylline concentration in the blood of children with persistently recurring bronchial asthma].
Gorshkova, IuG; Gusel', VA; Verbov, VN; Zisel'son, AD,
)
0.13
" Dose-response curves before and after insulin (10 U/kg) were identical in controls."( Restoration of coronary dilator action of adenosine in experimental diabetes.
Downing, SE, 1985
)
0.27
" Regression analysis revealed statistically significant dose-response relationships between peak increases in serum caffeine concentrations and increases in FEV1, FEF25-75%, and Gaw/VL from baseline values."( Bronchodilator effects of caffeine in coffee. A dose-response study of asthmatic subjects.
Gong, H; Hui, KK; Lee, EY; Simmons, MS; Tashkin, DP, 1986
)
0.27
" These results indicate that this simple method of Chiou may offer a reliable rapid estimation of total body clearance for dosage individualization in patients receiving intravenous aminophylline infusion."( Rapid estimation of total body clearance of theophylline in patients receiving intravenous aminophylline infusion.
Al-Bazzaz, FJ; Chiou, WL; Lam, G; Lau, AH; Lui, CY; O'Connor, T, 1986
)
0.68
" At the lower dosage of aminophylline the potential prophylactic and curative influence of aminophylline was tested using 3 different experimental paradigms performed on separate days: (1) Baseline force frequency responses were determined before and 15 and 35 min after a headlifting maneuver; headlifting resulted in a decrease in the 20/50 ratio (low frequency fatigue)."( Aminophylline and fatigue of the sternomastoid muscle.
Belman, MJ; Lewis, MI; Sieck, GC, 1986
)
2.02
" Appreciation of this potential variability is necessary for the proper interpretation of STC measurements and subsequent dosage adjustment."( Inconsistent absorption from a sustained-release theophylline preparation during continuous therapy in asthmatic children.
Kalisker, A; Rogers, RJ; Szefler, SJ; Wiener, MB, 1985
)
0.27
" Prediction of CL with either of the concentration-based methods studied will then allow safe and rapid adjustment of dosage to achieve therapeutic serum concentrations."( Estimation of theophylline clearance during intravenous aminophylline infusions.
Gilman, TM; Jung, RC; Muir, KT; Walberg, CB, 1985
)
0.52
" This case report demonstrates remarkable alterations in the CLT as a result of high doses of pentobarbital, necessitating the need for substantial dosage adjustments of theophylline."( Influence of high-dose pentobarbital on theophylline pharmacokinetics: a case report.
Bauer, LA; Blouin, RA; Gibson, GA; Rapp, RP; Tibbs, PA, 1985
)
0.27
" Prolonged treatment with nomifensin markedly reduced the response of the type I inhibitor both to low and high doses of apomorphine and shifted the dose-response curves to the right."( The responsiveness of the endogenous inhibitor of cAMP-dependent protein kinase to apomorphine in rat striatum after prolonged treatment with nomifensin.
Szmigielska, H; Szmigielski, A; Zalewska, J,
)
0.13
" In a preliminary experiment, the usual human dosage (milligram per kilogram) of each drug was given to 1 horse."( Theophylline and dyphylline pharmacokinetics in the horse.
Ayres, JW; Chang, SF; Pearson, EG; Riebold, TW, 1985
)
0.27
" Slow-release aminophylline in adequate dosage appears to be the most effective treatment yet demonstrated for nocturnal asthma."( Single-dose slow-release aminophylline at night prevents nocturnal asthma.
Barnes, PJ; Greening, AP; Neville, L; Poole, GW; Timmers, J, 1982
)
0.93
" Results of the electrocardiographic studies in heavy rats, using the calculated LD20 dosage of isoproterenol with or without pretreatment of aminophylline, demonstrated that both mortality and the arrhythmia-inducing effect of isoproterenol were significantly potentiated by aminophylline but only mortality was increased in small rats."( Enhancement of cardiotoxic effects of beta-adrenergic bronchodilators by aminophylline in experimental animals.
Balazs, T; Bloom, S; Joseph, X; Whitehurst, VE,
)
0.56
" In a period of eighteen months 1913 such assays were performed, and their influence on management was assessed by retrospective analysis in two groups--113 outpatients on stable dosage with no recent exacerbations of disease; and 28 inpatients and outpatients with concentrations exceeding 25 mg/l."( Theophylline prescribing, serum concentrations, and toxicity.
Geddes, DM; Johnson, MA; Woodcock, AA, 1983
)
0.27
" dosage with salbutamol (1-10 micrograms/kg), aminophylline (5-20 mg/kg) or ipratropium bromide (1-10 micrograms/kg) on total lung resistance in the anaesthetised state."( Pulmonary responses of salbutamol tolerant guinea-pigs to aminophylline and ipratropium bromide.
Tomlinson, DR; Ward, MJ, 1984
)
0.77
" Only 1 of the 21 patients met the criteria for dose dependency of a greater than or equal to 50% reduction in clearance with dosage increase."( Dose-dependent kinetics of theophylline in adults with pulmonary diseases.
Gotz, VP; Massey, KL; Russell, WL, 1984
)
0.27
" Based on the bioavailability and disposition kinetics of theophylline, an intragastric dosage regimen for aminophylline consisting of the administration of 5 mg/kg at 12 h intervals would be expected to maintain plasma theophylline concentrations within the therapeutic range."( Pharmacokinetics and bioavailability of theophylline in horses.
Baggot, JD; Button, C; Errecalde, JO; Mulders, MS, 1984
)
0.48
"5 hour after dosing had a significant decrease in PaCO2 (43."( Pharmacokinetic disposition of theophylline in horses after intravenous administration.
Beech, J; Kowalczyk, DF; Littlejohn, D, 1984
)
0.27
" There was no significant difference between treatments in serum theophylline levels fluctuations, although the dosing interval (12 hours) was twice as long for CR formulation."( [Chronic asthma in children: comparison between a delayed-action theophylline preparation and a prompt-release aminophylline preparation].
Longo, F; Longo, G; Poli, F; Strinati, R,
)
0.34
" In addition, in order to investigate dose-dependent kinetics for theophylline, the relationship between average plasma level and dosage was examined with Theona."( Pharmacokinetics of a sustained-release theophylline preparation in healthy subjects.
Goto, M; Nakamoto, Y; Sugiyama, M; Yamashina, H, 1983
)
0.27
" Plasma levels from 5 to 20 mg/l were measured after five days of treatment with either preparation given in average dosage of 10 mg Theophylline per kg body weight."( [Comparison of 2 theophylline delayed-action preparations of different galenic forms].
Hirsch, H, 1983
)
0.27
"9 X 10(-6) M, and the full dose-response curve spanned 2 log units from threshold to near maximum responses."( Effect of aminophylline on adenosine and exercise dilation of rat cremaster arterioles.
Heller, LJ; Mohrman, DE, 1984
)
0.67
" The method involves early determination of clearance from a nonsteady-state level, dosage adjustment on the basis of the estimated clearance, and measurement of serum theophylline concentration at a point very near steady state."( Rapid adjustment of theophylline: a kinetic model.
Jaresko, GS; Lesher, CA; Nitti, JR; Postelnick, MJ; Springborn, PW; Steiner, VI, 1984
)
0.27
" Repetitive cumulative dose-response curves demonstrated a progressive decline in the response of the pulmonary circulation to histamine."( Role of histamine in regulating pulmonary vascular tone and reactivity.
Bergofsky, EH; Mahoney, WA; Porcelli, RJ; Ventura, DF, 1981
)
0.26
" The subjects were divided into two groups (n = 6) with respect to smoking habit and on 4 separate occasions each received, on a randomized cross-over basis, a single dose of 400 mg equivalent of theophylline from every dosage form."( Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
Chiba, K; Echizen, H; Horai, Y; Ishizaki, T; Ohnishi, A; Sasaki, T; Suganuma, T, 1983
)
0.27
" For those patients with theophylline levels at the higher end of the therapeutic range (15 to 20 micrograms/ml), we recommend an initial 25% reduction in theophylline dosage when erythromycin is added."( The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis.
Melethil, S; Pingleton, SK; Reisz, G; Ryan, PB, 1983
)
0.27
" Whereas aminophylline in therapeutic dosage failed to provoke VE in arrhythmia-free COPD patients, the effect of aminophylline on pre-existent VE is variable."( The effect of aminophylline on cardiac rhythm in advanced chronic obstructive pulmonary disease: correlation with serum theophylline levels.
Au, WY; de Soyza, ND; Dutt, AK; Hargis, JL; Tuck, RL, 1983
)
1.04
" Authors confirm the usefulness of this product in childhood but dosage must be individualized with monitoring of theophylline blood levels."( [Therapy of bronchospasmic crisis of childhood with aminophylline].
Adamo, MC; Burrai, P; Corrias, A; Dolci, C; Puggioni, R; Rossi, G,
)
0.38
"Long-term treatment of childhood asthma with theophylline or theophylline ethylenediamine (Aminophyllin) preparations requires dosage according to the various age groups."( [Serum theophylline levels in aminophyllin treatment in children].
Alterthum, K; Bauer, P; Müller, G; Windorfer, A, 1982
)
0.26
" Theo-Dur dosing rates were calculated from the product of theophylline total body clearance and the desired steady-state theophylline concentration."( Conversion from intravenous to oral dosing using sustained-release theophylline tablets.
Haughey, DB; Ross, RJ; Stein, GE; Vakoutis, J, 1982
)
0.26
" Based on the pharmacokinetics of theophylline in the individual, the oral dosage of aminophylline was scheduled to attain steady-state trough theophylline concentrations (Cpred) near the therapeutic margin."( Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose.
Horai, Y; Ishizaki, T; Kabe, J; Sasaki, T; Watanabe, M, 1982
)
0.84
"Intravenous maintenance aminophylline infusion rate can be calculated from the previously received equivalent oral dosage in children with chronic asthma with considerable accuracy."( Intravenous maintenance aminophylline dosage in patients with asthma on regular oral theophylline.
Bell, TD; Chai, H; Chang, KC; Miles-Lawrence, R; Pinney, CT, 1982
)
0.88
" In both Groups I and II, our aminophylline dosage schedules, which consisted of intravenously administered boluses of 6 and 3 mg/kg followed by constant infusions of 1 mg/kg/h, resulted in serum theophylline levels that ranged from 12."( Aminophylline does not inhibit canine hypoxic pulmonary vasoconstriction.
Benumof, JL; Trousdale, FR, 1982
)
2
" Rat pups were given either aminophylline, theophylline, or caffeine in a dosage of 40 mg/kg or 80 mg/kg daily from the second postnatal day through 20 days of age."( A possible effect of the methylxanthines caffeine, theophylline and aminophylline on postnatal myelination of the rat brain.
Fuller, GN; Wiggins, RC, 1981
)
0.79
" Plasma concentrations during multiple dosing of the sustained release formulation were with one exception below 10 mg/l."( Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Molz, KH; Rietbrock, N; Schuppan, D; Staib, AH, 1981
)
0.51
" The advantages of the aerosol adrenergic agonists are the prompt onset of action and efficacy, small dosage preferentially delivered to the bronchial tree and lack of side effects."( Comparison of oral aminophylline and aerosol metaproterenol in asthma.
Shim, C; Williams, MH, 1981
)
0.59
" However, certain patients showed reductions in plasma theophylline clearance in the acute phase of the illness such that a dosage regimen standardised during remission may cause toxicity if continued in the acute episode."( A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission.
Arnold, JD; Hill, GN; Sansom, LN, 1981
)
0.26
" Maintenance dosing adjustments are then based on serum determinations and the presence of toxic effects."( Theophylline toxicity after the use of aminophylline in the treatment of cerebral vasospasm.
Bailey, RT; Blouin, RA; Rapp, RP; Young, B, 1981
)
0.53
" In addition, measurement of theophylline serum concentration is often necessary for optimum dosage adjustment."( [Relation of dose, serum concentration and side effects in intravenous aminophylline therapy].
Follath, F; Katz, G; Kewitz, G; Vozeh, S, 1981
)
0.5
" At no dosage level was there synergy between the two agents in terms of either mean percentage increase in FEV1 or the integrated response."( Intravenous salbutamol and aminophylline in asthma: a search for synergy.
Dart, AM; Davies, BH; Handslip, PD, 1981
)
0.56
" The clearance estimation methods were compared with the Food and Drug Administration (FDA) dosage guidelines and shown to be clearly superior in predicting therapeutic steady state theophylline concentrations."( Evaluation of two methods for estimating theophylline clearance prior to achieving steady state.
Anderson, G; Edwards, WD; Hook, E; Koup, J; Resman, B; Slaughter, R, 1981
)
0.26
" The dose-response and time-action parameters of theophylline's predisposing action to chloroform-hypoxia-induced cardiac arrhythmias were determined."( Development of a cardiac antiarrhythmic screening test utilizing theophylline in the rat.
Baker, T; Erker, EF, 1980
)
0.26
" Each dosage form contained approximately 250 mg of theophylline and was administered every eight hours."( A multiple-dose study of sustained-release theophylline and aminophylline.
Lieberman, P; Meyer, MC; Straughn, AB, 1980
)
0.5
"The bronchospasmolytic action of proxyphylline given intravenously in a dosage of 16 mg/kg body weight was assessed by spirometry and bodyplethysmography in 12 patients with chronic obstructive pulmonary disease."( [Effectiveness of proxyphylline in chronic obstructive pulmonary disease (author's transl)].
Förster, OB; Geisler, LS; Rohner, HG; Thiel, H, 1980
)
0.26
" Adenosine produced dose-dependent prolongation of A-V conduction time in both species, although guinea pig hearts responded to lower doses (10(-7) M) and showed a steeper dose-response relationship than rabbit hearts."( Atrioventricular conduction disturbances during hypoxia. Possible role of adenosine in rabbit and guinea pig heart.
Belardinelli, L; Belloni, FL; Berne, RM; Rubio, R, 1980
)
0.26
" 4 A nomogram for aminophylline dosage or monitoring of serum theophylline levels would have prevented little of the toxicity observed in these patients, although these measures would ensure that therapeutic concentrations were attained, and might prevent life-threatening toxicity."( Oral sustained-release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations.
Eppel, ML; Mackay, A; Oliver, JS; Ramsay, LE, 1980
)
0.91
" In a group treated with a low dosage of aminophylline, a significant increase of activity was found in all three nerves."( Changes in phrenic, hypoglossal and recurrent laryngeal nerve activities after intravenous infusions of aminophylline in cats.
Chiang, CH; Hwang, JC; Tang, YC; Wang, SE, 1995
)
0.77
"We studied the design of oral sustained-release theophylline dosing after conversion from constant aminophylline infusion."( The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.
Agata, H; Fukutomi, O; Imaeda, N; Kato, Z; Kondo, N; Kondo, T; Nakashima, Y; Orii, T; Shinoda, S; Yamazaki, M, 1994
)
0.51
" The reported highest dosage of acute ingestion was 1250 mg."( Profound shock resulting from a large dose of dipyridamole.
Chen, JH; Chen, ZC; Kwan, CM, 1994
)
0.29
" This emphasizes the need for well-designed research to develop optimal dosage regimens in paediatric patients with bronchiolitis."( Pattern of drug usage in bronchiolitis.
Nahata, MC; Schad, PA, 1994
)
0.29
" The dose-response curves for the effects of aminophylline in the presence of Ni2+ on Td and dT/dt max during direct single-pulse stimulation were significantly shifted to the right."( Some new evidence on antifatigue action of aminophylline on the isolated hemidiaphragm of the rat.
Prostran, M; Todorović, Z; Varagić, VM, 1993
)
0.81
" All products investigated rapidly discoloured during storage and none were considered to represent a realistic alternative to tableting technology for the production of a sustained-release oral dosage form of aminophylline."( Microencapsulation studies on aminophylline involving spherical crystallization, spheronization and drug loading on to non-pareil seeds.
Boles, MG; Deasy, PB; Donnellan, MF,
)
0.61
" Prolonged, 28 days treatment with lysine vasopressin (1 U/kg/day ip) induced hypertension and modified the dose-response curve for tremorine."( The responsiveness of M2-muscarinic receptors in the posterior hypothalamus and brain stem of vasopressin hypertensive rats.
Szadowska, A; Szmigielska, H; Szmigielski, A,
)
0.13
"8) and less total dosage (34 +/- 16 mg compared with 70 +/- 34 mg; mean difference, -36 mg; CI, -60."( Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma?
Aull, L; Harman, E; Hendeles, L; Huang, D; O'Brien, RG; Reents, S; Shieh, G; Visser, J, 1993
)
0.8
"There is a need to modify dosage schedule for these babies."( Kinetics of theophylline in apnea of prematurity in small for gestational age babies.
Bhakoo, ON; Chaudhuri, M; Garg, SK; Narang, A, 1996
)
0.29
") administered 30 min before and 6 h after antigen challenge (double dosing regimen), did not affect the development of the early or late phase responses."( Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration.
Broadley, KJ; Danahay, H, 1997
)
0.3
" Sinus bradycardia and A-V block induced by injection of exogenous adenosine were closely akin to those caused by myocardial hypoxia both in ECG characteristics and dose-response curve."( [Experimental study on adenosine hypothesis of bradyarrhythmias occurring in myocardial hypoxia and its clinical significance].
Sun, J; Xu, J; Yuan, F, 1996
)
0.29
"Nimodipine, a dihydropyridine derivative central nervous system (CNS) selective calcium channel blocker was studied at four different dosage schedules in five different models of seizures in rats."( Dose-finding study with nimodipine: a selective central nervous system calcium channel blocker on aminophylline induced seizure models in rats.
Chakrabarti, A; Garg, SK; Saini, HK, 1998
)
0.52
"To determine pharmacy impact on hospital costs, a retrospective chart review of IV aminophylline dosing requirements for 43 patients was undertaken."( Cost-saving impact of pharmacist-calculated i.v. aminophylline dosing schedules.
Bush, ND; Cook, CR, 1989
)
0.76
" Airway relaxant dose-response curves were constructed to measure isometric tension after administration of terbutaline (concentration range, 10(-8) to 10(-4) M), diltiazem (concentration range, 3 x 10(-7) to 1 x 10(-4) M), and aminophylline (concentration range, 10(-7) to 10(-4) M)."( Differential bronchodilatory effects of terbutaline, diltiazem, and aminophylline in canine intraparenchymal airways.
Akhtar, S; Bosnjak, Z; Cheng, EY; Kampine, JP; Mazzeo, AJ, 1999
)
0.72
"6 microgram/kg) and aminophylline (25 mg/kg), which were determined by the dose-response curves for inhibition of histamine-induced bronchoconstriction, were intravenously administered 5 minutes before the propranolol inhalation."( Difference in bronchoprotective effects of bronchodilators on postallergic propranolol-induced bronchoconstriction.
Fujimura, M; Ishiura, Y; Matsuda, T; Mizuhashi, K; Myou, S, 1999
)
0.63
" aminophylline infusion (total dosage 6 mg/kg within 15 minutes)."( The effect of aminophylline infusion on the exercise capacity in patients with syndrome X.
Sağkan, O; Uçar, R; Yazici, M; Yeşildağ, O; Yilmaz, O, 1999
)
1.57
" The following results were obtained: 1) Pharmacokinetic parameters of plasma theophylline after an intravenous bolus injection were close to those after the dosing of aminophylline in dogs by a crossover method."( Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine.
Kawai, H; Kojima, J; Kokubun, S; Matsumoto, T; Onodera, K, 2000
)
0.5
" The adverse events accompanying acute dosing are mild and transient."( The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent.
Greenway, FL, 2001
)
0.31
"A high-performance liquid chromatography procedure for the simultaneous determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in commercially available compound capsule dosage forms has been developed and validated."( HPLC determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in compound dosage forms with an aqueous-organic mobile phase.
Tang, C; Wu, X; Yin, C, 2003
)
0.86
" Sensitivity was high, results reproducible and linear log dose-response relationships obtained over a wide dosage range."( A method for the quantitative estimation of drugs on the isolated intact trachea.
JAMIESON, D, 1962
)
0.24
"The present work aimed to estimate the theophylline pharmacokinetic parameters (TH-PKP) in preterm neonates with apnea during the first month of life in order to optimize its dosage regimen."( Pharmacokinetics of theophylline in preterm neonates during the first month of life.
Ali, AS; Fida, NM; Islam, SI; Sheikh, AA, 2004
)
0.32
" These drug doses maximized survival duration in dose-response studies."( Adenosine A1 antagonism attenuates beta-adrenergic-resistant sudden hypoxic cardiac insufficiency.
Dalsey, WC; de Garavilla, L; Gao, E; Kaplan, JL; Victain, MS, 2005
)
0.33
"To investigate the effect of application and clinical value of use of epinephrine in graduate increased dosage according to the equation G=(K+2n-1)mg/3 minutes (K=1,2,n=1,2."( [Study on the value of the formula of rapid synchronous stepwise increase in dosage of epinephrine combined with aminophylline (7 mg/kg) in cardiopulmonary resuscitation].
Huang, X; Jiang, FZ; Shi, QB; Wang, GE; Xu, YS; Zhang, FX, 2008
)
0.56
"Due to missing information on appropriate dosing of aminophylline in meconium aspiration syndrome (MAS), this study compared effects of high-dose and low-dose aminophylline on lung function of animals with MAS."( Comparison of the effects of low-dose vs. high-dose aminophylline on lung function in experimental meconium aspiration syndrome.
Calkovska, A; Drgova, A; Mokra, D; Mokry, J; Petraskova, M; Pullmann, R; Redfors, B, 2008
)
0.85
" We hypothesized that aminophylline in the usual therapeutic dosage range, would elicit in the awake mammal, a significant increase in ventilation, and a significant increase in costal diaphragm shortening and contractility as recorded directly from the muscle."( Aminophylline increases ventilation and diaphragm contractility in awake canines.
Easton, PA; Hawes, HG; Jagers, JV, 2009
)
2.11
" A comparison of the PK profile with the oral dosing route of aminophylline was performed after delivery to the small bowel and colon."( Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules.
Cui, JG; Hou, WS; Liu, HY; Pi, XT; Zheng, XL, 2010
)
0.92
" This provides an opportunity for rational development of modified-release formulations as well as alternative dosage forms."( Pharmacokinetics of aminophylline delivered to the small intestine and colon using remote controlled capsules.
Cui, JG; Hou, WS; Liu, HY; Pi, XT; Zheng, XL, 2010
)
0.68
" Further more,the most efficient effects was showed in Limax lyophilized powder at the moderate dosage (63 mg/kg)."( [Effect of Limax lyophilized powder on bronchial asthma].
Lin, GQ; Luo, QF; Xie, JK; Yan, PK, 2011
)
0.37
" Higher Tmax, was found in the rabbits, dosed with F-II (12."( Preliminary evaluation of the in vitro release and in vivo absorption in rabbits of the modified-release dosage forms.
Djuric, ZR; Ibric, SR; Petricevic, SM; Petrovic, AA; Popovic, RB; Ristic, SM; Simic, SS, 2013
)
0.39
"01), hydrochlorothiazide dosing did not significantly change over the study period."( Initial experience using aminophylline to improve renal dysfunction in the pediatric cardiovascular ICU.
Anglemyer, AT; Axelrod, DM; Grimm, PC; Roth, SJ; Sherman-Levine, SF; Sutherland, SM; Zhu, A, 2014
)
0.71
"Human abdominal skin was dosed with 20 µL of either [(14)C]-aminophylline or [(14)C]-salicylic acid on 1 cm(2) per skin."( In vitro skin decontamination model: comparison of salicylic acid and aminophylline.
Blickenstaff, N; Coman, G; Maibach, H; Noury, B, 2015
)
0.89
" To help understand optimal aminophylline (salt formulation of theophylline) dosing strategies in this population, a population-based pharmacokinetic model was developed using nonlinear mixed-effects modeling (NONMEM) from 71 children (median age 5 months; 90% range 1 week to 10 years) who underwent cardiac surgery requiring CPB and received aminophylline as part of a previous randomized controlled trial."( Theophylline Population Pharmacokinetics and Dosing in Children Following Congenital Heart Surgery With Cardiopulmonary Bypass.
Axelrod, DM; Frymoyer, A; Grimm, PC; Su, F; Sutherland, SM, 2016
)
0.73
" Considering the long half-life of diazepam and its metabolites, concomitant use of theophylline may reduce the need for repeated dosing of flumazenil in patients with acute diazepam poisoning."( Determination of flumazenil in serum by liquid chromatography-mass spectrometry: Application to kinetics study in acute diazepam overdose.
Djordjević, S; Jović-Stosić, J; Kilibarda, V; Perković-Vukcević, N; Segrt, Z, 2016
)
0.43
" This review aims to evaluate the evidence for the optimum dosage strategy of intravenous aminophylline in children suffering an exacerbation of asthma."( Aminophylline Dosage In Asthma Exacerbations in Children: A Systematic Review.
Cooney, L; Hawcutt, D; Sinha, I, 2016
)
2.1
"A systematic review comparing dosage regimens of intravenous aminophylline in children suffering an exacerbation of asthma."( Aminophylline Dosage In Asthma Exacerbations in Children: A Systematic Review.
Cooney, L; Hawcutt, D; Sinha, I, 2016
)
2.12
"Studies using intravenous aminophylline in children with an acute exacerbation of asthma which reported the dosage and clinical outcomes."( Aminophylline Dosage In Asthma Exacerbations in Children: A Systematic Review.
Cooney, L; Hawcutt, D; Sinha, I, 2016
)
2.18
" There is a poor relationship between the dosage administered to children and symptom resolution, length of stay or need for mechanical ventilation."( Aminophylline Dosage In Asthma Exacerbations in Children: A Systematic Review.
Cooney, L; Hawcutt, D; Sinha, I, 2016
)
1.88
"The currently recommended dosage regimens may not represent the optimum safety and efficacy of intravenous aminophylline."( Aminophylline Dosage In Asthma Exacerbations in Children: A Systematic Review.
Cooney, L; Hawcutt, D; Sinha, I, 2016
)
2.09
" Current aminophylline iv loading dosage recommendations achieve levels <10 mg/l in 70% of children."( Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations.
Cooney, L; Hawcutt, DB; Johnson, TN; Lilley, A; McBride, A; Sinha, I, 2017
)
1.1
"Aminophylline is as effective as caffeine for prevention of apneic spells in preterm neonates; however, dosage optimization needs to be done to reduce toxicity."( Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial.
Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017
)
2.15
" Because, as opposed to the diuretic effect, the side effect profile of aminophylline is dose-dependent, low maintenance dosing may optimize the balance between providing adjunctive diuretic effect while minimizing the risk of toxicity."( No Requirement for Targeted Theophylline Levels for Diuretic Effect of Aminophylline in Critically Ill Children.
Halstead, ES; Park, K; Tamburro, RF; Trout, LC; Wang, M; Xu, C, 2018
)
0.95
" We evaluated the pharmacokinetics and dose-exposure relationships of theophylline in this population to guide dosing strategies."( Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Chock, VY; Christians, U; Drover, DR; Frymoyer, A; Klawitter, J; Van Meurs, KP, 2020
)
0.56
" The ability of different dosing regimens to achieve target concentrations (4-10 mg/L) associated with clinical response was examined."( Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Chock, VY; Christians, U; Drover, DR; Frymoyer, A; Klawitter, J; Van Meurs, KP, 2020
)
0.56
" Dosing strategies need to consider the unique pharmacokinetic needs of this population."( Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Chock, VY; Christians, U; Drover, DR; Frymoyer, A; Klawitter, J; Van Meurs, KP, 2020
)
0.56
" As theophylline is advanced in clinical development, dosing strategies will need to consider the unique pharmacokinetic needs of neonates with HIE undergoing therapeutic hypothermia."( Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Chock, VY; Christians, U; Drover, DR; Frymoyer, A; Klawitter, J; Van Meurs, KP, 2020
)
0.56
" Steady-state predictions supported twice daily dosing of the OFT, but specific dosage recommendations are hindered by lack of a canine-specific therapeutic range for plasma theophylline concentration."( Pharmacokinetics of a 503B outsourcing facility-produced theophylline in dogs.
de Oliveira, GAR; Forsythe, L; Li, Z; Reinhart, JM, 2022
)
0.72
" We found a large heterogeneity regarding sample size, age and gender distribution, inclusion criteria (different severity scores, if any) and ketamine dosing (bolus and/or continuous infusion)."( Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies.
Astuto, M; Brancati, S; Crimi, C; Cuttone, G; Dezio, V; Falcone, M; La Via, L; Sanfilippo, F, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
bronchodilator agentAn agent that causes an increase in the expansion of a bronchus or bronchial tubes.
cardiotonic drugA drug that has a strengthening effect on the heart or that can increase cardiac output.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
mixtureA mixture is a chemical substance composed of multiple molecules, at least two of which are of a different kind.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.68340.100020.879379.4328AID588453
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1468
lamin isoform A-delta10Homo sapiens (human)Potency3.31170.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)131.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (95)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID76173Effect on heart rate 5(mins) after intravenous administration in anesthetized guinea pigs1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID210479Tested in vitro against rabbit thromboxane A2 synthetase (TXA2) at 1 uM1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID76171Effect on heart rate 1(mins) after intravenous administration in anesthetized guinea pigs.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID77922Effect on left ventricular dP/dtmax 0(mins) after intravenous administration in anesthetized guinea pigs.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID77397Reversal of spasmogen-induced contraction of guinea pig cylindrical tracheal segments induced by histamine (1x 0e -5 M)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.
AID1291204Inhibition of Ach-induced contraction in Sprague-Dawley rat trachea2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
New isosteroidal alkaloids with tracheal relaxant effect from the bulbs of Fritillaria pallidiflora Schrenk.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID212107Tested for inhibition of thromboxane A2 (TXA2) production in rat serum by ex vivo assay after peroral dose of 30 mg/kg1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones.
AID403111Inhibition of PDE in Sprague-Dawley rat epididymal adipose tissue assessed as [14C]adenosine recovery at 1 mM by liquid scintillation counting1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue.
AID78313In vitro inhibitory effect on the spasmogen-contracted guinea pig tracheal strips in presence of acetylcholine1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID1348548Anti-asthmatic activity in guinea pig tracheal smooth muscle ring assessed as reduction in acetylcholine-induced muscle contractions after 60 mins2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID76951Effect of the compound (peroral administration) on anaphylactic bronchoconstriction in passively sensitized guinea pigs.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID212106Tested for inhibition of thromboxane A2 (TXA2) production in rabbit by in vitro assay at 1 uM1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID73834Tested in vitro for bronchodilatory activity by spontaneous tone inhibition in guinea pig tracheal strips1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones.
AID77464Tested in vivo for anaphylactic bronchoconstriction in OA sensitized guinea pig at intraduodenal dose of 10 mg/kg for 30 min1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID1147855Bronchodilator activity in guinea pig assessed as protection against histamine aerosol-induced bronchoconstriction at 75 mg/kg, ip treated for 15 mins prior to histamine aerosol-challenge measured after 5 mins relative to control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Dibenzotropone- and dibenzosuberonecarboxylic acids with bronchodilator activity.
AID428067Vasorelaxant activity against carbachol chloride-induced contraction in guinea pig trachea treated 30 mins after carbachol chloride challenge2009Journal of natural products, Jun, Volume: 72, Issue:6
Solving the confusion of gnaphaliin structure: gnaphaliin A and gnaphaliin B identified as active principles of Gnaphalium liebmannii with tracheal smooth muscle relaxant properties.
AID75770Oral antiallergic activity in the Guinea Pig Anaphylaxis (GPA) at the dose of 31.6 mg/kg; 6 guinea pigs were challenged with the antigen1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis and antiallergy activity of N-[2-(dimethylamino)ethyl]-4-aryl-1-piperazinecarboxamide derivatives.
AID210482Tested ex vivo against TXA2 production in rat serum at 1 hr after peroral dose of 30 mg/kg and anesthetized with ether1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID77612Intrinsic activity measured on Guinea pig tracheal spiral strips.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID1348549Agonist activity at beta-adrenergic receptor in rat airway smooth muscle cells assessed as reduction in acetylcholine-induced muscle contractions by measuring cAMP levels after 18 hrs post acetylcholine stimulation by ELISA (Rvb = 8.402 +/- 0.041 nmol/l)2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID73835In vitro bronchodilatory activity in guinea pig isolated tracheal strips1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID77923Effect on left ventricular dP/dtmax 1(mins) after intravenous administration in anesthetized guinea pigs.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID1348547Anti-asthmatic activity in guinea pig tracheal smooth muscle ring assessed as reduction in acetylcholine-induced muscle contractions by measuring muscle relaxation at 1.25 mmol/l after 60 mins (Rvb = 13.59 +/- 9.14%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID76858Percent inhibition of bronchospasm, when administered orally at a dose of 18 mg/kg in guinea pig1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Antiallergy agents. 1. Substituted 1,8-naphthyridin-2(1H)-ones as inhibitors of SRS-A release.
AID1348546Anti-asthmatic activity in guinea pig tracheal smooth muscle ring assessed as reduction in acetylcholine-induced muscle contractions by measuring muscle relaxation at 0.75 mmol/l after 60 mins (Rvb = 7.73 +/- 4.81%)2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID76859Percent inhibition of bronchospasm, when administered orally at a dose of 53 mg/kg in guinea pig1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Antiallergy agents. 1. Substituted 1,8-naphthyridin-2(1H)-ones as inhibitors of SRS-A release.
AID1291202Inhibition of Ach-induced contraction in Sprague-Dawley rat trachea at 1 to 100 umol/L2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
New isosteroidal alkaloids with tracheal relaxant effect from the bulbs of Fritillaria pallidiflora Schrenk.
AID76091Inhibitory effect on spasmogen (carbachol) induced contraction of guinea pig tracheal strips.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID76393Inhibition of spontaneous tone in Guinea pig tracheal spiral strips.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID78276Effect on carbachol induced contraction of guinea pig tracheal strips1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.
AID76950Effect of the compound (intravenous administration) on anaphylactic bronchoconstriction in passively sensitized guinea pigs.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID77924Effect on left ventricular dP/dtmax 3(mins) after intravenous administration in anesthetized guinea pigs1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID78274Schultz-Dale (SD) reaction in tracheal strip isolated from passively sensitized guinea pigs1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID78346In vivo inhibitory effect on airway constriction induced by histamine 2-5 micro g/kg iv at 1 min after 10 mg/kg intravenous dose in anesthetized guinea pigs1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1147854Bronchodilator activity in guinea pig assessed as protection against histamine aerosol-induced bronchoconstriction at 50 mg/kg, ip treated for 15 mins prior to histamine aerosol-challenge measured after 5 mins relative to control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Dibenzotropone- and dibenzosuberonecarboxylic acids with bronchodilator activity.
AID77467Tested in vivo for histamine-induced bronchoconstriction in guinea pig at intraduodenal dose of 60 mg/kg1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID77103In vitro reversal of spasmogen-induced contraction of guinea pig cylindrical tracheal segments induced by 20 mM of potassium chloride1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID14902Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.
AID76172Effect on heart rate 3(mins) after intravenous administration in anesthetized guinea pigs1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID77391Reversal of spasmogen-induced contraction of guinea pig cylindrical tracheal segments induced by 5-hydroxytryptamine (2x 10e-6 M)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID223059Effect on heart rate 0(mins) after intravenous administration in anesthetized guinea pigs.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID78314In vitro inhibitory effect on the spasmogen-contracted guinea pig tracheal strips in presence of histamine1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID76088Inhibition of the Schulz-Dale (SD) reaction-induced contraction in trachea of guinea pig1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID76739Percent inhibition of bronchospasm, when administered orally at a dose of 160 mg/kg to guinea pig1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Antiallergy agents. 1. Substituted 1,8-naphthyridin-2(1H)-ones as inhibitors of SRS-A release.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID78312In vitro inhibitory effect on the contraction of guinea pig tracheal strips was examined for spontaneous contraction1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID76916Tested in vivo for spasmogen inhalation induced collapse in conscious guinea pig in presence of acetylcholine (0.2%)1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID77925Effect on left ventricular dP/dtmax 5(mins) after intravenous administration in anesthetized guinea pigs1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID78275Effect on LTD4 induced contraction of guinea pig tracheal strips1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.
AID77394Reversal of spasmogen-induced contraction of guinea pig cylindrical tracheal segments induced by acetylcholine (1 x 10e -5 M)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.
AID192856Compound was evaluated for Serum creatinine concentration in glycerol injected rats treated with 10 mg/kg administered intraperitoneally.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID192858Compound was evaluated for Urea Nitrogen concentration in glycerol injected rats treated with 10 mg/kg administered intraperitoneally.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.
AID76917Tested in vivo for spasmogen inhalation induced collapse in conscious guinea pig in presence of histamine (0.03%)1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID76092Inhibitory effect on spasmogen (histamine) induced contraction of guinea pig tracheal strips.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID158571Inhibition of guinea pig Phosphodiesterase1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Antiinflammatory activity of a series of substituted 2,3-dihydro-6-hydroxypyrimido[2,1-f]purine-4,8(1H,9H)-diones.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID220537Inotropic activity against guinea pig spontaneously beating atria1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and biological evaluation of substituted benzo[h]cinnolinones and 3H-benzo[6,7]cyclohepta[1,2-c]pyridazinones: higher homologues of the antihypertensive and antithrombotic 5H-indeno[1,2-c]pyridazinones.
AID78347In vivo inhibitory effect on airway constriction induced by histamine 2-5 micro g/kg iv at 1 min after 10 mg/kg iv dose of compound1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.
AID1147852Bronchodilator activity in guinea pig assessed as protection against histamine aerosol-induced bronchoconstriction at 100 mg/kg, ip treated for 15 mins prior to histamine aerosol-challenge measured after 5 mins relative to control1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Dibenzotropone- and dibenzosuberonecarboxylic acids with bronchodilator activity.
AID76093Inhibitory effect on spasmogen (leukotriene, LTD4) induced contraction of guinea pig tracheal strips.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
New bronchodilators. 1. 1,5-Substituted 1H-imidazo[4,5-c]quinolin-4(5H)-ones.
AID159525Percent inhibition of Canine Tracheal Smooth Muscle PDE 4 at 100 uM1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.
AID78277Effect on histamine induced contraction of guinea pig tracheal strips1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,928)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902806 (71.44)18.7374
1990's566 (14.41)18.2507
2000's300 (7.64)29.6817
2010's207 (5.27)24.3611
2020's49 (1.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.20 (24.57)
Research Supply Index8.46 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index149.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (81.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials447 (10.46%)5.53%
Reviews195 (4.56%)6.00%
Case Studies254 (5.95%)4.05%
Observational3 (0.07%)0.25%
Other3,373 (78.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (33)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Aminophylline Bolus Versus Infusion on Recovery Time in Patients Undergoing Lumbar Spine Surgery: Double Blind Randomized Controlled Trial [NCT05655806]Phase 433 participants (Anticipated)Interventional2022-12-30Recruiting
Assessing the Impact of Aminophylline in the Reversal of Complete Heart Block Secondary to Inferior Wall MI in Atropine Resistant Patients: An Open Label Non-randomized Clinical Trial [NCT05666219]Phase 473 participants (Anticipated)Interventional2022-12-19Not yet recruiting
MK-476 IV Formulation Phase III Open Label Exploratory Comparative Study - Acute Exacerbations of Asthma - [NCT00442338]Phase 391 participants (Actual)Interventional2007-03-31Completed
Aminophylline for Patients With Post-Dural Puncture Headache: a Prospective, Multi-center, Randomized Controlled Trial [NCT02522013]Phase 3126 participants (Actual)Interventional2015-10-31Completed
Effect of Intravenous Aminophylline on Hemodynamics and Recovery of Patients Undergoing Functional Endoscopic Sinus Surgery Under Dexmedetomidine Hypotensive Anesthesia: A Randomized Controlled Study [NCT05738135]52 participants (Actual)Interventional2023-02-25Completed
Effects of Aminophylline Bolus on Eleveld and Schnider TCI (Target Controlled Infusion) Concentrations at Start and End of Burst Suppression Occurence and on BIS (Bispectral Index) During the Induction Phase of Total Intravenous Anaesthesia With TCI [NCT06134037]32 participants (Anticipated)Observational2023-11-12Recruiting
Effects of Aminophylline Bolus on Eleveld and Schnider TCI (Target Controlled Infusion) Concentrations at Return of Responsiveness and on BIS (Bispectral Index) After Total Intravenous Anaesthesia With TCI [NCT06098196]48 participants (Anticipated)Observational2023-10-25Recruiting
[NCT01280071]0 participants InterventionalNot yet recruiting
Impacts of Aminophylline on Perioperative Lung Mechanics in COPD Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery: A Prospective Randomized Double Blinded Trial [NCT06125665]60 participants (Anticipated)Interventional2023-11-11Recruiting
Is Aminophylline More Effective Than Neostigmine/Atropine Mixture in the Treatment of Post-dural Puncture Headache: A Randomized Clinical Trial [NCT03997006]Phase 460 participants (Actual)Interventional2019-01-01Completed
Aminophylline Improves Early Postoperative Cognitive Recovery After Sevoflurane Anaesthesia: A Dose-Dependent Study [NCT01022151]Phase 2180 participants (Actual)Interventional2007-11-30Completed
The Effect of Aminophylline on Preventing Acute Kidney Injury in Pediatric Patients Undergoing Open Heart Surgery [NCT03897335]Phase 380 participants (Anticipated)Interventional2019-02-07Recruiting
The Effect of Preoperative Aminophylline on the Recovery Profile After Major Pelvi-abdominal Surgeries: Randomized Controlled Double Blinded Study [NCT04151381]Phase 145 participants (Anticipated)Interventional2019-11-30Recruiting
Clinical Study on the Efficacy of Compound Sodium Chlorate and Aminophylline Tablets for Mild to Moderate Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD). [NCT04101500]Phase 4200 participants (Anticipated)Interventional2019-04-01Recruiting
Diuretic Efficacy of Aminophylline and Furosemide Combination vs Furosemide Alone in Critically Ill Adults [NCT05933642]Phase 2/Phase 3132 participants (Anticipated)Interventional2023-07-02Recruiting
Trans-nasal Sphenopalatine Ganglion Block Versus Intravenous Aminophylline Injection for Treatment of Postdural Puncture Headache After Caesarean Section Under Spinal Anesthesia [NCT05552404]Phase 475 participants (Actual)Interventional2022-10-01Completed
A Phase I Trial to Determine the Safety, Tolerability and Maximum Tolerated Intravesical Dose of Aminophylline With BCG in Patients With Non-invasive Bladder Cancer [NCT01240824]Early Phase 13 participants (Actual)Interventional2010-07-31Completed
A Randomized Double-Blind Placebo Controlled Study With Aminophylline to Attenuate the Side Effect Profile of Regadenoson in Patients Undergoing Myocardial Perfusion Imaging. [NCT01250496]Phase 4248 participants (Actual)Interventional2010-11-30Terminated(stopped due to Due to nationwide shortage of Aminophylline. Enrolled subjects did not complete study.)
A Randomised Controlled Feasibility Study of the Tolerability of the Combination of Progesterone and Aminophylline for the Prevention of Preterm Labour [NCT03152942]Phase 170 participants (Anticipated)Interventional2017-10-05Recruiting
Perioperative Aminophylline to Improve High Risk Renal Graft Outcome- a Double Blinded, Placebo Controlled, Randomized Clinical Trial [NCT01759862]50 participants (Actual)Interventional2012-11-30Completed
A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics [NCT02270827]5 participants (Actual)Observational2014-06-30Terminated(stopped due to Study was set up by an MSc student who left her post.)
Aminophylline in Bradyasystolic Cardiac Arrest: A Randomized Placebo-Controlled Trial [NCT00312273]Phase 2966 participants Interventional2001-01-31Completed
The Impact of Routine Administration of Aminophylline Following Regadenoson According to the ASSUAGE Protocol on the Accuracy of Regadenoson Stress Myocardial Perfusion Imaging: A Single-Blinded Cross-Over Clinical Trial [NCT01655524]Phase 40 participants (Actual)Interventional2012-07-31Withdrawn(stopped due to Due to nationwide shortage of Aminophylline. No subjects enrolled.)
A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass [NCT01245595]144 participants (Actual)Interventional2010-11-30Completed
The Safety Evaluation of Aminophylline and Methazolamide When Administered Orally Alone and in Combination to Healthy Volunteers [NCT01587027]Phase 116 participants (Actual)Interventional2011-12-31Completed
Effect of Aminophylline on Contrast Induced Acute Kidney Injury in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty [NCT01594489]Phase 4250 participants (Actual)Interventional2009-01-31Completed
Effects of Aminophylline on Renal Function and Urine Volume Acute Kidney Injury Patient [NCT02983422]Early Phase 160 participants (Anticipated)Interventional2016-12-31Not yet recruiting
A Randomized, 4-Sequence, Double-Blind Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude [NCT01794078]Phase 192 participants (Actual)Interventional2013-09-30Completed
Effect of Intraoperative Aminophylline Infusion on Pain Intensity After Ureterocopic Lithotripsy Surgeries [NCT05705050]50 participants (Actual)Interventional2023-02-15Completed
A Prospective Open Randomized Clinical Trial of Non-invasive Ventilation Versus Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma. [NCT03296579]100 participants (Anticipated)Interventional2018-06-30Not yet recruiting
The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers [NCT01530464]Phase 118 participants (Actual)Interventional2012-02-29Completed
Attenuation of the Side Effect Profile Of Regadenoson: A Randomized Double-Blind Placebo-Controlled Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging and Have Severe Chronic Kidney Disease (ASSUAGE-CKD Trial) [NCT01336140]Phase 4300 participants (Actual)Interventional2011-06-30Completed
Rapid Acclimatization to Hypoxia at Altitude [NCT01702025]Phase 1/Phase 241 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00442338 (1) [back to overview]Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration
NCT01245595 (1) [back to overview]Acute Kidney Injury Measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine Criteria
NCT01250496 (2) [back to overview]"Number of Participants With Composite Endpoint of Any Regadenoson-related Side Effects."
NCT01250496 (2) [back to overview]Composite Endpoints of Abdominal Cramps and Diarrhea.
NCT01336140 (4) [back to overview]Diarrhea (as Reported by the Patient)
NCT01336140 (4) [back to overview]Global Symptom Score (GSS) of Regadenoson Related Adverse-effects
NCT01336140 (4) [back to overview]Number of Patients With Any (One or More) Regadenoson-related Adverse-effect
NCT01336140 (4) [back to overview]Patients With Recorded Aminophylline Related Major Adverse Events
NCT01530464 (6) [back to overview]Area Under the Curve Post Dosing (AUC_0-infinity) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination
NCT01530464 (6) [back to overview]Area Under the Curve Within 24 Hours Post Dosing (AUC_0-24 Hours) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination
NCT01530464 (6) [back to overview]Maximum Plasma Concentration (Cmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination
NCT01530464 (6) [back to overview]Plasma Halflife of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination
NCT01530464 (6) [back to overview]Time Until Maximum Plasma Concentration (Tmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination
NCT01530464 (6) [back to overview]Mean Number of Adverse Events Following Each Dose
NCT01587027 (1) [back to overview]Adverse Events.
NCT01702025 (1) [back to overview]Magnitude of Decrement in Exercise Time Trial Performance in Hypoxia (Low Oxygen) Compared With Normoxia (Normal Oxygen).
NCT01759862 (3) [back to overview]Calculated Estimated Glomerular Filtration Rate (eGFR)
NCT01759862 (3) [back to overview]Presence of Fibrosis Measured on Protocol Biopsy
NCT01759862 (3) [back to overview]Urinary NGAL (Neutrophil Gelatinase-associated Lipocalin)/ Creatinine Ratio

Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration

The time weighted average change from Baseline in Forced Expiratory Volume in One Second (FEV1) over the first 60 minutes after study drug administration (average change FEV1 (0-60 min)). Baseline (pre-allocation) was the last measurement obtained during the screening period. (NCT00442338)
Timeframe: Baseline and 60 minutes after study drug administration

InterventionLiter (Least Squares Mean)
Montelukast 7 mg0.07
Montelukast 14 mg0.05
Aminophylline 250 mg0.06

[back to top]

Acute Kidney Injury Measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine Criteria

Acute Kidney Injury measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine criteria; KDIGO Stage is a measure of acute kidney injury. (NCT01245595)
Timeframe: 5 days

Interventionparticipants (Number)
Aminophylline43
Placebo36

[back to top]

"Number of Participants With Composite Endpoint of Any Regadenoson-related Side Effects."

"The secondary end-point encompasses any one (or more) regadenoson-related side effects of flushing /feeling hot, chest pain /chest discomfort, angina, headache, dizziness, abdominal cramps/discomfort, diarrhea, and/or nausea.~If multiple side effects occur only one side effect is counted." (NCT01250496)
Timeframe: within 2 hours from the intervention.

Interventionparticipants (Number)
Aminophylline55
Placebo83

[back to top]

Composite Endpoints of Abdominal Cramps and Diarrhea.

Patients will be surveyed for these symptoms following to the completion of the cardiac stress testing procedure and prior to discharge from the laboratory. (NCT01250496)
Timeframe: within 2 hours from the intervention.

InterventionParticipants (Count of Participants)
Aminophylline11
Placebo22

[back to top]

Diarrhea (as Reported by the Patient)

"Number of patients who report any incident of diarrhea. Patients will be surveyed for incidents of diarrhea following to the completion of the cardiac stress testing procedure and prior to discharge from the laboratory (typically within 2 hours from stress completion).~The primary endpoint encompasses the number of patients with reported symptoms of diarrhea, not the number of bowel movements." (NCT01336140)
Timeframe: Within 2 hours from the intervention

Interventionparticipants (Number)
Aminophylline9
Placebo26

[back to top] [back to top] [back to top] [back to top]

Area Under the Curve Post Dosing (AUC_0-infinity) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination

"Aminophylline Alone (Single Dose of 500mg Aminophylline) Aminophylline in Presence of Ambrisentan (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan) Ambrisentan Alone (Single Dose of 5mg Ambrisentan) Ambrisentan in Presence of Aminophylline (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan)~Blood sample collections for plasma Ambrisentan and Theophylline determinations at 0-hour (pre-dose), and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose" (NCT01530464)
Timeframe: 24h after dosing

Interventionh*ng/ml (Median)
Aminophylline Alone99799.27
Aminophylline in Presence of Ambrisentan88545.08
Ambrisentan Alone3703.01
Ambrisentan in Presence of Aminophylline3779.21

[back to top]

Area Under the Curve Within 24 Hours Post Dosing (AUC_0-24 Hours) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination

"Aminophylline Alone (Single Dose of 500mg Aminophylline) Aminophylline in Presence of Ambrisentan (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan) Ambrisentan Alone (Single Dose of 5mg Ambrisentan) Ambrisentan in Presence of Aminophylline (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan)~Blood sample collections for plasma Ambrisentan and Theophylline determinations at 0-hour (pre-dose), and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose" (NCT01530464)
Timeframe: 24h after dosing

Interventionh*ng/ml (Median)
Aminophylline Alone75970.66
Aminophylline in Presence of Ambrisentan74451.38
Ambrisentan Alone3225.47
Ambrisentan in Presence of Aminophylline3338.09

[back to top]

Maximum Plasma Concentration (Cmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination

Aminophylline Alone (Single Dose of 500mg Aminophylline) Aminophylline in Presence of Ambrisentan (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan) Ambrisentan Alone (Single Dose of 5mg Ambrisentan) Ambrisentan in Presence of Aminophylline (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan) (NCT01530464)
Timeframe: 24h after dosing

Interventionng/ml (Median)
Aminophylline Alone6590
Aminophylline in Presence of Ambrisentan6780
Ambrisentan Alone464.5
Ambrisentan in Presence of Aminophylline562

[back to top]

Plasma Halflife of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination

"Aminophylline Alone (Single Dose of 500mg Aminophylline) Aminophylline in Presence of Ambrisentan (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan) Ambrisentan Alone (Single Dose of 5mg Ambrisentan) Ambrisentan in Presence of Aminophylline (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan)~Blood sample collections for plasma Ambrisentan and Theophylline determinations at 0-hour (pre-dose), and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose" (NCT01530464)
Timeframe: 24 hours after dosing

Interventionhours (Median)
Aminophylline Alone11.11
Aminophylline in Presence of Ambrisentan9.96
Ambrisentan Alone8.27
Ambrisentan in Presence of Aminophylline9.12

[back to top]

Time Until Maximum Plasma Concentration (Tmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination

"Aminophylline Alone (Single Dose of 500mg Aminophylline) Aminophylline in Presence of Ambrisentan (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan) Ambrisentan Alone (Single Dose of 5mg Ambrisentan) Ambrisentan in Presence of Aminophylline (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan)~Blood sample collections for plasma Ambrisentan and Theophylline determinations at 0-hour (pre-dose), and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose" (NCT01530464)
Timeframe: 24h after dosing

Interventionhours (Median)
Aminophylline Alone2.0
Aminophylline in Presence of Ambrisentan1.50
Ambrisentan Alone2.0
Ambrisentan in Presence of Aminophylline2.0

[back to top]

Mean Number of Adverse Events Following Each Dose

"Dosing schedule:~Aminophylline Alone (Single Dose of 500mg Aminophylline) Ambrisentan Alone (Single Dose of 5mg Ambrisentan) Ambrisentan and Aminophylline (Combined Single Dose of 500mg Aminophylline and 5mg Ambrisentan)" (NCT01530464)
Timeframe: 48 h following each dose

,
InterventionMean number of adverse events (Mean)
Adverse Events after aminophyllineAdverse Events after ambrisentanAdverse Events after combined treatment
Sequence A2.50.82.7
Sequence B0.40.40.5

[back to top]

Adverse Events.

Adverse event data was evaluated for incidence and severity for 6 days. (NCT01587027)
Timeframe: 6 days.

InterventionEvents (Number)
Sequence A29
Sequence B40

[back to top]

Magnitude of Decrement in Exercise Time Trial Performance in Hypoxia (Low Oxygen) Compared With Normoxia (Normal Oxygen).

After exercising on a stationary cycle ergometer for 30 minutes at a resistance of 100 watts, research participants will complete an exercise time trial. The time taken to cycle a distance equivalent to 7.75 miles will be recorded. On a separate day the experiment will be repeated in hypoxia. It is expected that the time taken to cycle a distance equivalent to 7.75 miles will be longer in hypoxia compared to normoxia. One of the goals of this research is to determine if the hypoxia-mediated performance decrement can be decreased with one of our pharmacological interventions. (NCT01702025)
Timeframe: The exercise trial will begin within 5 hours of exposure to either normoxia or hypoxia

Interventionminutes (Mean)
Normoxia Placebo22.3
Hypoxia Placebo25.2
Normoxia Aminophylline22.2
Hypoxia Aminophylline24.0
Normoxia Methazolamide23.0
Hypoxia Methazolamide24.6
Normoxia Methazolamide/Aminophylline24.5
Hypoxia Methazolamide/Aminophylline25.9

[back to top]

Calculated Estimated Glomerular Filtration Rate (eGFR)

The investigators will measure blood creatinine on post-operative day 5 and using the Schwartz equation will calculate estimated glomerular filtration rate (GFR) to determine kidney function. (NCT01759862)
Timeframe: 5 days

Interventionml/min/1.73m2 (Mean)
Aminophylline67.39
Control80.48

[back to top]

Presence of Fibrosis Measured on Protocol Biopsy

The investigators will use the same cores that are obtained during routine 6 months protocol biopsies to quantify the amount of fibrosis (NCT01759862)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Aminophylline11
Control14

[back to top]

Urinary NGAL (Neutrophil Gelatinase-associated Lipocalin)/ Creatinine Ratio

urinary NGAL(Neutrophil gelatinase-associated lipocalin) is a biomarker for kidney injury. NGAL levels 12h post-transplant were found to be a marker for development of delayed graft function and need for dialysis post-transplant. NGAL levels are corrected for urine creatinine. (NCT01759862)
Timeframe: 12 hours post transplant

Interventionng/mg (Median)
Aminophylline300.5
Control425.4

[back to top]